Innate Immunity and Biomaterials at the Nexus: Friends or Foes

Susan N. Christo,1 Kerrilyn R. Diener,1,2 Akash Bachhuka,3 Krasimir Vasilev,3 and John D. Hayball1,4

1 Experimental Therapeutics Laboratory, Sansom Institute and Hanson Institute, School of Pharmacy and Medical Science, University of South Australia, Adelaide, SA 5000, Australia
2 Robinson Research Institute, School of Paediatrics and Reproductive Health, University of Adelaide, Adelaide, SA 5005, Australia
3 Mawson Institute, University of South Australia, Adelaide, SA 5095, Australia
4 School of Medicine, University of Adelaide, Adelaide, SA 5005, Australia

Correspondence should be addressed to John D. Hayball; john.hayball@unisa.edu.au

Received 22 January 2015; Revised 15 June 2015; Accepted 22 June 2015

Academic Editor: Konstantinos Michalakis

Copyright © 2015 Susan N. Christo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Biomaterial implants are an established part of medical practice, encompassing a broad range of devices that widely differ in function and structural composition. However, one common property amongst biomaterials is the induction of the foreign body response: an acute sterile inflammatory reaction which overlaps with tissue vascularisation and remodelling and ultimately fibrotic encapsulation of the biomaterial to prevent further interaction with host tissue. Severity and clinical manifestation of the biomaterial-induced foreign body response are different for each biomaterial, with cases of incompatibility often associated with loss of function. However, unravelling the mechanisms that progress to the formation of the fibrotic capsule highlights the tightly intertwined nature of immunological responses to a seemingly noncanonical “antigen.” In this review, we detail the pathways associated with the foreign body response and describe possible mechanisms of immune involvement that can be targeted. We also discuss methods of modulating the immune response by altering the physiochemical surface properties of the biomaterial prior to implantation. Developments in these areas are reliant on reproducible and effective animal models and may allow a “combined” immunomodulatory approach of adapting surface properties of biomaterials, as well as treating key immune pathways to ultimately reduce the negative consequences of biomaterial implantation.

1. Introduction

The role of implantable biomaterials is to replace or enhance biological function or offer structural support in host tissue [1, 2]. Biomaterials can be used for different lengths of time within the host depending on the intended purpose. Temporary biomaterials include contraceptive implants [3–5], pins for bone reconstruction and bone lengthening [6, 7], certain dental implants prior to restoration [8], catheters [9], stents [10], and some dermal fillers used for cosmetics and facial reconstruction [11, 12]. However, the majority of implantable biomaterials are intended for the duration of the host’s lifetime. These biomaterials encompass a range of applications in many tissue types but are most prominent in and for orthopaedics [13, 14], dental settings [15, 16], cardiac pacemakers [17, 18], and glucose biosensors [19–21]. Unfortunately, invasive implantation methods, such as surgery, potentiate an unavoidable adverse host response [22] in which the biomaterial itself determines the duration of the inflammatory response. These negative consequences may contribute to the ultimate failure of the device, reducing the lifespan of the biomaterial and necessitating additional implantations [23–25]. Therefore, the longevity of the biomaterial is central to the aims of manufacturing and design whilst upholding maximum biological functionality. The aim of biomaterial research is to develop biocompatible devices that can be integrated into tissue and perform their intended functionality with minimal damage or negative response to the host [1].
2. The Foreign Body Response to Implantable Biomaterials

The utility and function of biomaterial implants can be compromised by the development of a foreign body reaction (FBR): an acute sterile innate immune inflammatory reaction which overlaps with tissue vascularisation and remodelling and ultimately fibrotic encapsulation to prevent further interaction with the host tissue (Figure 1) [26–28]. All biomaterial implants have the capacity to induce a FBR; however the severity and clinical manifestation of these responses can widely differ [29]. Here, the pathways involved in the FBR are summarised, and the reader is directed to more detailed accounts of protein and cellular responses elsewhere [22, 30].

2.1. Protein Adsorption onto the Biomaterial Surface. The FBR is initiated within seconds of implantation [31], characterised by rapid and spontaneous adsorption and deadsorption of host serum proteins (the Vroman effect [32]) including albumin, fibrinogen, fibronectin, vitronectin, gamma globulin, complement, and other immunomodulatory proteins (Figure 1(a)) [33–37]. The resulting thrombus formation defines the provisional matrix around the biomaterial [38–41], leading to the aggregation of activated platelets and fibrin, which is formed upon thrombin-mediated conversion of fibrinogen [42]. Fibrinogen has also been shown to activate platelets [43, 44], and both fibrin and fibrinogen can recruit additional immune cells to the site of the biomaterial [45, 46]. Biomaterial-adsorbed vitronectin can enhance cell adhesion [47–49], whereas an additional adhesion protein, fibronectin, is suggested to partake in the chronic phase of the FBR [50, 51]. Importantly, this highlights how the provisional matrix is a milieu rich in activating and immunomodulatory molecules that direct acute inflammatory mechanisms [30].

2.2. Acute Inflammation in the FBR Cascade. Central to acute inflammation are the recruitment and activation of neutrophils (Figure 1(b)), which rapidly localise to the implantation site upon release of chemotactants by activated platelets [52, 53] and endothelial cells [54–57]. Neutrophils attempt to destroy the biomaterial by mechanisms intrinsic to their function, which include phagocytosis and degranulation for the release of proteolytic enzymes and reactive oxygen species (ROS) [58–63]. More recently, neutrophils have been shown to release neutrophil extracellular traps (NETs) [64], comprised of a “network” of granular proteins, neutrophil elastase, chromatin DNA, and histones [65]. The “sticky” nature of these NETs is used to “trap” pathogens and prevent spread of infection, as well as possessing bactericidal activity [64]. However, the involvement of NETs, if any, has not been detailed for implantable biomaterial-induced inflammation.

In parallel to neutrophil recruitment, circulating monocytes can respond to platelet-derived chemotactants localised to the implantation site [30] and bind the protein layer on the biomaterial via fibrinogen, resulting in their activation (Figure 1(b)) [51, 66, 67]. At the site of injury, these monocytes differentiate into classically activated or “M1” macrophages [68], defined by their ability to secrete proinflammatory cytokines, including interleukin (IL)-1β, IL-6, IL-8 and tumour necrosis factor (TNF)α, and chemokines [68, 69]. Adherent macrophages also attempt to degrade the biomaterial by releasing ROS and degradative enzymes [70, 71], before undergoing “frustrated” phagocytosis because the biomaterial is too large to internalise, ultimately resulting in an exerted increase in proinflammatory cytokines [72, 73]. Analogous to wound healing events [74], biomaterial-adherent macrophages eventually transition into an alternatively activated or “M2” phenotype [75], characterised by reduced degradative capacity, secretion of anti-inflammatory cytokines, such as IL-10, and gained tissue remodelling functionality. The overlapping events of the phenotypic M1 to M2 switch as well as the mechanisms of frustrated phagocytosis results in the fusion of macrophages into a foreign body giant cell (FBGC) on the biomaterial surface in an attempt to increase their phagocytic functionality [71, 76].

2.3. Chronic Inflammation in the FBR Results in Reduced Biomaterial Function. The formation of FBGCs is often a signature component of biomaterial-induced FBR and is instigated through the activation of mast cells, basophils, and T helper (Th) cells that secrete IL-4 and IL-13 secretion known to induce macrophage fusion (Figure 1(c)) [77–79]. Mast cells are consistently reported at the site of implantation [80–82] and have demonstrated activation-induced degranulation and the secretion of pro- and anti-inflammatory cytokines, albeit at lower concentrations, as well as angiogenic and profibrotic factors, including vascular endothelial growth factor (VEGF) and transforming growth factor (TGF)-β [83–88]. However, the role of mast cells in the FBR has been recently questioned when Yang et al. (2014) did not observe reduced or abrogated FBR markers in mast cell-deficient mice [89]. The role of T cells in the FBR has also been investigated when Rodriguez et al. (2009) demonstrated that, similarly, T cell-deficient mice were able to generate “normal” FBGCs and the FBR [90]. Both studies suggested the potential of compensatory mechanisms to account for their observations [91]. The involvement of T cells in the FBR to nonphagocytosable implants has not been fully elucidated; however T cells have been shown to attach to the biomaterial [92] and become activated through noncanonical pathways [93–96], as well as enhancing macrophage adhesion and fusion into FBGCs through paracrine actions of secreted cytokines [97–99]. The concerted action of immune cells results in pathways directed at isolating the biomaterial from the host tissue by fibrotic encapsulation [100] by the release profibrogenic factors such as platelet-derived growth factor (PDGF) [101–103], VEGF [104, 105], and TGF-β [106, 107] that recruit fibroblasts to the biomaterial (Figure 1(c)). Whilst the exact mechanisms of fibroblast recruitment have not been fully described, it has been suggested that biomaterial-adherent FBGCs serve as a constant source of fibrogenic mediators; however this remains to be tested [22]. Activated fibroblasts deposit collagen in an attempt to repair the damaged tissue; however excessive secretion results in fibrosis [108] and, in the case of implantation, forms a capsule around the biomaterial.
Figure 1: Foreign body response to biomaterials. The foreign body response is an acute inflammatory reaction which overlaps with tissue vascularisation and remodelling and ultimately fibrotic encapsulation. (a) Upon implantation, blood proteins are immediately adsorbed and instigate the formation of a thrombus, which acts as a provisional matrix rich in factors that recruit innate leukocytes. (b) Neutrophils are recruited to the site of implantation and attempt to degrade the biomaterial. Monocytes are also recruited and mature into macrophages, which undergo differentiation from an M1 and M2 phenotype and ultimately exhaust their phagocytic capacity. (c) Adaptive leukocytes, such as T cells and mast cells, are recruited and secrete cytokines that encourage foreign body giant cell (FBGC) formation. Fibroblast recruiting factors are secreted by FBGCs and result in their activation and collagen deposition, ultimately forming a capsule around the biomaterial to prevent further interaction with the host tissue.
Underpinning the FBR

The activation of leukocytes throughout the FBR is governed by controlled mechanisms that underpin innate immunity. Recognition and activation by leukocytes are dependent on surface receptor interactions that can be used to “sense” harmful situations. Evolutionary mechanisms that can detect foreign “stranger” pathogens are described by the interactions of pattern recognition receptors (PRRs) expressed on leukocytes with pathogen-associated molecular patterns (PAMPs) found on microorganisms [115]. These same PRRs can also recognise host “danger,” which may be induced by cell death, damage, or stress and can evoke immune responses. These responses are driven by molecules within the family of damage-associated molecular patterns (DAMPs). In the context of implantation, biomaterials are considered to induce “sterile” inflammation; therefore, the involvement of innate recognition and response mechanisms to DAMPs, which may be released by cells throughout the FBR, are described.

3.1. Stranger Danger: Outside the Cell Walls of Comfort. A subset of DAMPs are “alarmins” [116], which are endogenous molecules constitutively expressed and stored within intracellular compartments and, upon exposure to extracellular spaces, through passive release or active secretion, can evoke recruitment and activation of leukocytes [117]. Alarmins can be divided into eight categories, including cathelicidin, defensins, eosinophil-associated ribonucleases, heat shock proteins, ion-binding proteins, saposin-like granulysin, nucleotides/metabolites, and nucleotide-binding proteins [117]. Within the nucleotide-binding proteins category, high mobility group box 1 (HMGB1) is exemplarily as it fulfils all the requirements associated with an alarmin, which include (i) passive or active secretion following nonprogrammed or apoptotic cell death, respectively; (ii) production by immune cells without the need for dying; (iii) the ability to recruit and activate leukocytes; and (iv) involvement in reconstructing damaged tissue [118, 119]. Originally recognised for its role as a chromatin-associated protein involved in DNA transcription [120, 121], HMGB1 has since been described to present a role in danger sensing [122] and has since been associated with several pathologies including fibrotic diseases [123]. Extracellular HMGB1 is a result of passive release from necrotic cells [124] or active secretion from leukocytes [125] and can act on a range of receptors, including receptor for advanced glycation end products (RAGE), which instigates its functionality [126]. In addition, HMGB1 has been reported as a chemoattractant for monocytes, macrophages, and dendritic cells (DCs) [127, 128] which is reliant on forming complexes with other cytokines [127]. The release of HMGB1 from platelets has also demonstrated the capacity to stimulate neutrophils as detected by ROS secretion [129]. A growing number of investigations have implicated a role for HMGB1 in fibrotic diseases, with increased levels of HMGB1 in patients that have systemic sclerosis [123, 130], cystic fibrosis [131, 132], liver fibrosis [133], or pulmonary fibrosis [134, 135]. In these settings, HMGB1 has been shown to affect fibroblast proliferation [136–138], migration [138, 139], and collagen synthesis [133, 137, 138] and enhance proinflammatory cytokine secretion [138, 140, 141]. Indeed, blocking HMGB1 with small interfering RNA in a murine model of liver fibrosis inhibited collagen production [133], whereas the injection of recombinant HMGB1 into mice could induce lung pathologies similar to that observed in cystic fibrosis [132]. There are limited reports investigating HMGB1 in biomaterial-related responses; however, one study that used poly(lactic-co-glycolic acid) scaffolds as a model of subcutaneous biomaterial implantation could detect HMGB1 at the site of scaffold implantation but not in animals that underwent surgery without receiving the scaffold. This suggested that HMGB1 may be released by necrotic cells or lymphocytes due to tissue damage at the implantation site [142]. Ongoing investigation of extracellular HMGB1 in biomaterial-induced inflammation could be of considerable value as several methods of therapeutic or prophylactic HMGB1 blockade/inhibition have already been established in various in vivo models, which, with further exploration, may also be advantageous in situations of surgical biomaterial implantation where risks of tissue damage are high.

An additional nucleotide-binding alarmin, IL-33, may also be of interest for biomaterial investigations [117]. In a similar manner to HMGB1, IL-33 can act as both a cytokine and a nuclear factor and has been linked to fibrosis through the actions of leukocyte recruitment and modulation of ECM genes [143, 144]. Expression of IL-33 has also been shown to be increased in patients with idiopathic pulmonary fibrosis and liver fibrosis [145–147]. In murine models, overexpression of IL-33 in hepatocytes caused an excessive local immune cell infiltration and increased hepatic collagen deposition. This was however abrogated in IL-33−/− mice, suggesting that IL-33 has a role in driving ECM deposition [148]. Furthermore, systemic administration of IL-33 to mice resulted in increased mRNA levels of IL-13 and the development of skin fibrosis [143]. In a manner relevant to its alarmin function, IL-33 is constitutively expressed and is released during necrosis as an active protein [145]. If IL-33 release is accompanied by the presence of neutrophils at a local injury site, serine proteases, cathepsin G, and elastase can cleave IL-33 to generate a “superactive” form of the protein [149, 150]. Upon secretion, IL-33 has been found to be a chemoattractant for Th2 cells [151], as well as acting directly on Th2 cells via constitutively expressed (protein
of growth stimulation gene 2) ST2 receptor [152, 153] to induce the secretion of IL-13 [153, 154], an important cytokine detailed in FBGC formation. There are currently no studies that directly assess the involvement of IL-33 in biomaterial-induced inflammation; however the emerging links between IL-33 and fibrotic disorders might suggest that release of IL-33 at the biomaterial implantation site by necrotic cells may encourage the cytokine milieu that results in FBGC release and collagen deposition. Further assessment may qualify IL-33 as an additional candidate for therapeutic blockade to reduce the FBR.

3.2. Integrin Receptors. Traditionally viewed as adhesion receptors, integrin receptors have demonstrated their capacity to independently recognise DAMPs to induce immune responses. There are 22 integrin receptors in mammals based on the combinations of different α and β chain subtypes (17 α subunits and 8 β subunits) which form noncovalent heterodimers [155, 156]. The observation that integrin receptors can mediate proinflammatory cytokine release upon activation by bacterial components [157–159] was instigated by a study in 2005 that reported on how integrin ligands could prompt recognition by leukocytes [160]. Vorup-Jensen and colleagues demonstrated that the integrins α5β2 (CD11c/CD18) and αvβ3 (Mac-1; CD11b/CD18) could recognise acidic residues exposed on proteins that were degraded by the action of bacteria-derived proteases [160]. The significance of this study was that misfolded or degraded proteins could be recognised by leukocyte-expressing receptors, which is not only engendered by bacterial challenges, but present in ECM remodelling processes [160]. In particular, fibrinogen is commonly investigated because it can bind several integrins through its arginine-glycine-aspartic acid (RGD) sequence [161], which is also found in other integrin ligands [155, 162] such as fibronectin [163] and vitronectin [164]. Interestingly, fibrinogen absorbed onto the biomaterial may alter its conformation due to chemical and physical properties, exposing RGD for leukocyte recognition via Mac-1, and initiate integrin signalling [165–167]. Therefore, the susceptibility of fibrinogen to lose structural integrity and bind leukocyte receptors may suggest that fibrinogen acts as a sentinel of tissue damage [160].

3.3. Toll-Like Receptors. Pattern recognition receptors are traditionally divided into five main families: toll-like receptors (TLRs), nucleotide-binding oligomerization domain- (NOD-) like receptors (NLRs), absent in melanoma- (AIM-) like receptors (ALRs), retinoic acid-inducible gene I- (RIG-I-) like receptors (RLRs), and the C-type lectin receptors (CLRs) [115, 168]. For the purpose of this review, TLRs, NLRs, and ALRs in the context of biomaterial-induced responses will be discussed.

There are 10 TLRs in humans [169, 170] and 12 TLRs in mice [169, 171], but both present as transmembrane receptors found on the plasma membrane and endosome/lysosome membranes [115] for PAMP and DAMP detection. Toll-like receptors are characterised by an extracellular leucine-rich repeat (LRR) and an intracellular toll/IL-1 receptor (TIR) domain [172]. Upon recognition of their distinguished ligands (reviewed elsewhere [173]), TLR signalling pathways can induce the secretion of proinflammatory cytokines or type one interferons, as mediated by the myeloid differentiation primary response gene 88 (MyD88) or TIR-domain-containing adapter-inducing interferon-β (TRIF) adaptor proteins, respectively [174].

Despite the predominant investigation of TLRs in inflammation and infection, reports of TLR involvement in the context of biomaterials are now being described, mostly for phagocytosable particles, including implant aseptic and septic loosening due to wear debris. It has been extensively demonstrated that TLR2 and TLR4 play a role in recognising the subclinical levels of bacterial contamination that drive implant loosening [175–178]; however it has also been shown that in vivo oxidised alkane polymers can directly induce TLR1/2 signalling [179]. In a subsequent in vitro model, oxidised alkanes were shown to have 140 times greater binding affinity to soluble TLR2 than the nonoxidised polymer [179]. These results begin to detail the innate response following the degradation of common materials used for implants; however further investigations are required to assess TLR interaction with nonphagocytosable biomaterials. With a focus on DC functionality, Shokouhi et al. (2010) used MyD88-deficient DCs for an assessment of global TLR actions in biomaterial responses [180]. The results of the study demonstrated that in comparison to wild-type DCs, MyD88-deficient DCs had lower surface marker expression and decreased cytokine secretion when they were incubated on a range of biomaterials. Individual TLR-deficient DCs were also subject to the same analysis and it was revealed that TLR1, TLR2, TLR4, and TLR6 had a role in recognising and responding to biomaterials as DC functionality was abolished or strongly impaired in these cells compared to wild-type DCs [180]. The importance of TLR4 was also observed by Rogers and Babensee (2010) in a study highlighting the effect of TLR4 on leukocyte recruitment, adhesion, and fibrotic encapsulation [181]. Interestingly, the results of this study did not define a role for TLR4 in the recruitment of leukocytes, the TNFα levels in peritoneal exudates, or the thickness of the fibrotic capsule. Instead, TLR4 deficiency seemed to impart differences in the profiles of adherent leukocytes on the biomaterial surface. The TLR4-deficient mice appeared to have increased neutrophils and decreased monocytes/macrophages adhered onto the biomaterial, in comparison to the TLR4-sufficient control mice [181].

In 2004, Seong and Matzinger proposed the hydrophobicity model to explain mechanisms of alarmin recognition by TLRs [182], an idea which may be plausible for the results observed in biomaterial models. The hydrophobicity model [183] stems from the understanding that hydrophobic portions or "hypos" of molecules are usually hidden from the aqueous environment by conformational folding that result in functional aggregates. However, in situations when hypos are exposed, specifically in damaged tissue, these regions act as universal signals of homeostatic disruption due to protein misfolding and potentially toxic and nonproductive aggregates, which are recognised by TLRs [182]. To date, this serves as a good model for justifying TLR involvement in biomaterial responses in sterile inflammation.
Additionally, the hydrophobicity model may explain the fact why fibrinogen can act as an alarmin and has been shown to be a TLR4 ligand, presumably through the exposure of the RGD domain [184–188]. Other ECM proteins associated with biomaterial adhesion have also been reported as TLR ligands [189], including fibronectin [187, 190], as well as proteins associated with damage such as HMGB1 [191, 192]. The significance of understanding the roles of TLRs in FBRs was recently demonstrated in a study assessing the therapeutic efficacy of a TLR2/6 agonist. In this study, porous polyethylene (commercially known as Medpor) is used for craniofacial reconstructive surgery; however, adequate tissue integration relies on rapid vascularisation [193]. To this end, macrophage-activating lipopeptide-2, a TLR2/6 agonist, was locally injected into preclinical models investigating Medpor. The treatment was shown to increase vascularisation 14 days after implantation and did not cause local or systemic side effects as determined by control animals [193]. This study highlights the fact that targeting specific TLR pathways can force a desired response and therefore manipulating TLR signalling could potentially be used to control the FBR [194].

3.4. Cytosolic Sensors and the Associated Inflammasomes That Control the Release of Potent Proinflammatory Cytokines.

Whilst the TLR family can detect extracellular signals, the NLRs are soluble proteins located in the cytosol for intracellular monitoring of a broad repertoire of PAMPs and DAMPs [195]. Structurally, NLRs are composed of three domains: (i) the C-terminal domain containing LRRs involved in ligand sensing, (ii) a central nucleotide domain, NACHT domain (also referred to as NOD), responsible for oligomerization of NLRs, and (iii) the N-terminal effector domain that differs based on its exclusive composition of a caspase activation and recruitment domain (CARD), a pyrin domain (PYD), or a baculovirus inhibitor of apoptosis repeat (BIR) domain [196, 197]. The structural and functional diversity of domain composition classifies NLRs in three subfamilies: (i) NLRPs (also referred to as NALPs) based on PYD as the N-terminal, (ii) NODs which predominantly express CARD (also referred to as NLRCs), and (iii) the IPAF/NAIP (IL-1ß-converting enzyme protease-activating factor/NLR family, apoptosis inhibitory protein) family whereby IPAF (synonymous with NLRC4) contains a CARD, and NAIF contains BIR domains (also referred to as NLRBs) [196]. Together, these cytosolic sensors can detect ligands from invading sources and initiate signalling pathways that result in the secretion in cytokines, interferons, and microbicidal proteins.

A unique feature of some PRRs, including NLRs, is the ability to form an inflammasome. The term “inflammasome” was coined by Martinon et al. (2002) to describe high molecular weight complexes due to multiprotein assembly that activate inflammatory caspases and result in IL-1ß secretion (Figure 2) [198]. The pioneering work of the Tschopp laboratory has led to the identification of seven inflammasomes, each named after their protein scaffold, including the NLRP1, NLRP3, NLRP6, NLRP12, IPAF inflammasomes, and, more recently, the IFI16 and AIM2 inflammasomes [197, 198]. The AIM2 and IFI16 proteins are two of eight cytosolic sensors in mice that comprise the ALR family [199], all of which contain a HIN200 (hematopoietic interferon-inducible nuclear antigens with a 200-amino acid repeat) domain at the C-terminal and can directly bind double stranded DNA (dsDNA) from various sources [200]. In particular, the AIM2 protein is not as structurally diverse as NLRs, as the C-terminal HIN200 domain is complemented with an N-terminal PYD [201]. The formation of canonical inflammasomes, regardless of sensor protein, relies on homotypic interactions between equivalent domains on target proteins. Therefore, upon activation of the cytosolic sensors, inflammasome assembly is initiated by the recruitment and binding of ASC (apoptosis-associated speck-like protein containing a caspase recruitment domain, also referred to as PYCARD) via PYD-PYD interactions [200, 202]. The C-terminal CARD of ASC facilitates interactions with the CARD of procaspase-1, resulting in its self-activation into caspase 1 by proteolytic cleavage into the active heterodimer comprised of 10 and 10 kDa subunits (p10 and p20, resp.) [203]. Together, the interactions between the cytosolic sensors, the ASC adaptor protein, and caspase 1 form the inflammasome (Figure 2). Structurally, inflammasomes may resemble the “apoptosome” required for caspase 9 activation based on the potential to form a double-ringed “wheel” structure of the multiple heterotetramers complexes [204, 205]. The central aggregation of caspase 1 is thought to lock caspase 1 into an enzymatically active state to facilitate the cleavage of pro-IL-1ß and pro-IL-18 into their biologically active forms, IL-1ß, and IL-18, respectively (Figure 2) [206].

Another outcome of inflammasome activation is a form of nonhomeostatic and lytic mode of cell death, termed pyroptosis, which requires the activity of caspase 1 or caspase 11 depending on the stimuli [204]. The activation of caspase 11 has been implicated in inflammasome activation and, however, is unable to process pro-IL-1ß and pro-IL-18 directly influences inflammasome-mediated pyroptosis [204, 207]. Interestingly, cytokine production precedes the induction of pyroptosis, suggesting that the cell inflicts maximal inflammation to promote immune activation prior to its death. It is thought that pyroptosis serves to prevent intracellular pathogen replication by eliminating the infected cell and also enhancing pathogenic recognition by exposing the pathogen to circulating neutrophils and phagocytes [204]. Consequently, cells that have undergone pyroptosis may also release endogenous molecules into the extracellular milieu as danger signals, of which HMGB1 and IL-1α have shown to be passively secreted [208–211], further perpetuating the inflammatory response. Considering the potent nature of IL-1ß and IL-18, it is understandable that inflammasomes require regulators to control activation and efficiently subside inflammatory signals. The two major types of inflammasome regulators are proteins that contain either a CARD to prevent ASC recruitment or PYD-containing proteins to disrupt sensor-ASC interactions [212, 213]. Together, PRRs and inflammasomes present an impressive and controlled mechanism for alerting the host of stranger and danger signals.

3.5. Activating the NLRP3 and AIM2 Inflammasomes. Traditionally, inflammasomes are concerned with the control of invading pathogens such as bacteria [214, 215], viruses
forms, respectively. Interestingly, TLR-induced NF-$\kappa$B or fungi [218, 219] by secreting IL-1$\beta$, which is a potent proinflammatory cytokine. It is recognised that NLRP3 inflammasome activation requires two signals. The first signal is a "priming" step and results in the production of pro-IL-1$\beta$ via transcription factor NF$\kappa$B-mediated regulation, commonly achieved by TLR stimulation [220]. Interestingly, TLR-induced NF$\kappa$B activation has also been implicated in the transcriptional control of NLRP3 and can increase NLRP3 expression to potentiate intracellular sensing [221, 222]. Unlike pro-IL-1$\beta$ transcription, pro-IL-18 is constitutively expressed in macrophages and does not rely on NF$\kappa$B-mediated transcription [223, 224]. The second signal required for NLRP3 activation consists of a broad range of infection or stress-associated signals, and due to the diverse nature of these signals, it is unlikely that direct interactions with NLRP3 would induce its activation [197]. Instead, NLRP3 activation has been implicated to occur through the induction by three main methods: (i) ion flux, (ii) ROS, and (iii) lysosome rupture [197]. In the ion flux method, changes to cytosol concentrations of hydrogen (H$^+$), calcium (Ca$^{2+}$), or potassium (K$^+$) ions disrupt intracellular homeostasis and activate NLRP3. In particular, extracellular ATP released from damaged or stressed cells can act on the P2X7 ion channel to trigger K$^+$ efflux [225–227]. Endothelial and epithelial cells have been shown to release ATP in situations of mechanically induced stress such as compression [228], stretching [229], and changes in blood flow [230] and may result in K$^+$ efflux [196]. Similarly, H$^+$ efflux or toxic levels of cytosolic Ca$^{2+}$ can activate the NLRP3 inflammasome [220, 231, 232].

The second method is defined by the release of ROS as an indicator of oxidative stress, which is induced by many NLRP3 stimuli such as ATP, alum, uric acid, or nigericin [226, 233, 234]. However the role of ROS in NLRP3 activation remains controversial. Contradicting reports suggest that ROS solely acts to upregulate NLRP3 and pro-IL-1$\beta$ expression in an NF$\kappa$B-dependent manner [235], and other studies demonstrated how ROS can be sensed by a complex of Thioredoxin (TXN) and TXN interacting protein (TXNIP) which binds to NLRP in conditions of oxidative stress [236]. Recently, Shimada et al. (2012) proposed a unified model of NLRP3 activation and suggested that, in the presence of signal one, the NLRP3 stimuli can cause mitochondrial dysfunction, resulting in apoptosis and NLRP3 activation [237]. This study also demonstrated that apoptosis results in the release of ROS and mitochondrial DNA and that oxidised mitochondrial DNA could directly interact with NLRP3 as observed by immunoprecipitation [237].

The third method for NLRP3 activation is based on the detection of lysosome rupture during frustrated phagocytosis caused by large particulates, including uric acid crystals, alum, silica, and asbestos [233, 238]. It was demonstrated that frustrated phagocytosis could alter the cytoskeleton, and upon disruption of the actin filaments with cytochalasin D, the secretion of IL-1$\beta$ was inhibited [238]. Furthermore, NLRP3 activation can be subsided with the treatment of cathepsin B, a lysosomal protease inhibitor [233]. Despite the understanding of downstream responses of phagocytosis of particulates, the exact molecular links that connect these events to NLRP3 activation remain to be elucidated [233].

Originally documented as a cytosolic HIN200 family protein for binding dsDNA, AIM2 was recently identified as an inflammasome-inducing sensor that could aggregate with caspase 1 and ASC [200]. The activation mechanisms of the AIM2 inflammasomes have not been detailed to the same extent as NLRP3 but do not appear to rely on a two-hit signal model, most likely due to the unambiguous HIN200 domain.
3.6. The Role of Inflammasomes in Biomaterial-Induced Inflammation

The observation that phagocytosable particles, such as asbestos and silica, could activate NLRP3 inflammasomes was investigated to understand the fibrotic diseases they caused [238]. Asbestos is an insulating material that was widely used in construction around the 1970s and was later discovered to cause several lung-related diseases including mesothelioma, lung cancer, and asbestosis [245]. Crystalline silica (silicon dioxide) is the most abundant mineral worldwide and is commonly encountered in areas of mining, construction, and farming. Inhalation of silica is associated with numerous pathologies including tuberculosis, lung cancer, chronic obstructive pulmonary disease, and silicosis [246]. The observation that alveolar macrophages could secrete IL-1β upon asbestos or silica exposure naturally led to the discovery that NLRP3 was involved in their related pathologies [238, 247]. The mechanisms of NLRP3 activation by asbestos and silica particles are similar to those described for invading pathogens. Both asbestos and silica can induce the generation of ROS [247–249] and, in the case of asbestos, works to indirectly activate NLRP3 by irreversibly oxidising TXN, resulting in the dissociation of TXN-TXNIP and subsequent binding of TXNIP with NLRP3 [250]. Thus, the roles of asbestos and silica seem to be indirect, whereby particle phagocytosis results in lysosomal swelling and damage, allowing NLRP3 to “sense” this perturbation [233]. The activation of the NLRP3 inflammasome has been implicated in driving inflammatory responses to nanoparticulate carbon [251] and polystyrene [252], as well as nanodebris typically derived from implants [253] including amorphous silica and titanium dioxide (TiO₂) [254], CoCrMo [255], and silver [256] (reviewed in [257]). However, it is unclear whether the NLRP3 activation mechanisms induced by these materials are consistent amongst the various phagocytosable particles.

The involvement of the inflammasome has also been implicated for large biomaterials that cannot be phagocytosed or do not generate wear debris or particulates. Detection of IL-1β at the local implant site [258] and in vitro quantification of IL-1β secretion by biomaterial-adherent macrophages [259, 260] suggest, at least in part, a role for the inflammasome in biomaterial-induced inflammation, although inflammasome-independent pathways of IL-1β secretion have recently been described [261–263]. The proposed models of NLRP3 inflammasome activation also overlap with certain events described within the FBR, such as ROS production by neutrophils and frustrated phagocytosis by macrophages. The associated tissue damage of implantation may also result in ATP release through mechanically induced cell stress leading to K⁺ efflux; however this has not been directly shown in the FBR and further investigation is required to decipher if there are any correlative relationships between these events and NLRP3 inflammasome activation. Malik et al. (2011) were the first to demonstrate the direct involvement of ASC and caspase 1 in the progression of FBR events, with mice deficient in these components exhibiting thinner fibrotic capsules around silicone disk implants at 4 weeks after implantation [264]. Interestingly, the absence of NLRP3 or NLRC4 sensors did not affect capsule thickness compared to controls, and this may suggest the involvement of another ASC-dependent inflammasome or, alternatively, inflammasome activation-independent mechanisms [215, 265, 266] that can indirectly affect the FBR. However, when assessing “acute” stages of FBR with the injection of PMMA beads of ~153 µm diameters, NLRP3, ASC, and caspase 1 were involved in leukocyte recruitment within 24 hrs [264]. The results of this study also supported a recently described method of inflammasome activation, independent of phagosomal disruption. It was shown that interactions of solid structures with the cholesterol regions of lipid rafts of the cell membrane could activate the Syk kinase [267]. Malik et al. (2011) showed a reduction in IL-1β secretion when macrophages were pretreated with a cholesterol-depletion agent or a Syk inhibitor, supporting a membrane affinity triggered signalling (MATS) mode of inflammasome activation [264]. This was an extension from a study that investigated how DC activation could be induced via surface contact with particulates, namely, MSU crystals. The authors proposed a two-step process: firstly the MSU crystal lattice is aligned with cholesterol in the DC membrane to form tight interactions within 30 seconds of contact, which leads to lipid rearrangement. Secondly this lipid sorting results in the aggregation of immunoreceptor tyrosine-based activation motif- (ITAM-) containing receptors into cholesterol/sphingolipid rich regions of lipid rafts and initiates Syk kinase pathways [267]. Therefore, understanding the mechanisms of potential inflammasome components that are activated by large biomaterials and contribute to the FBR may result in clinically translatable methods of reducing inflammatory outcomes, such as kinase inhibitors [268] or the IL-1 receptor (IL-1R) antagonist, anakinra [269].

A current gap in the literature is the role of the AIM2 inflammasome in sterile environments, particularly in biomaterial-induced inflammation. Further investigation of AIM2 in these pathologies is not unwarranted on the basis that AIM2 can recognise self-dsDNA as a product of DAMP-induced cell death and may affirm an indirect role of alarmins. We have recently begun exploring the role of AIM2 in biomaterial-induced inflammation by adapting the model of PMMA bead injection [264] to induce pathways of the FBR in a murine model. Results in AIM2−/− mice demonstrated a reduced capacity of neutrophils and macrophages to migrate...
4.1. Surface Chemistry. The understanding that surface functionality alters protein adhesion and directs downstream cell recruitment has led to the global aim of producing “repellent” surfaces to moderate protein binding [273]. Methods of altering surface chemistry are vast but may be achieved by chemical grafting, self-assembled monolayers, or plasma polymerisation, and each has been tested for ultimately controlling the amount and composition of protein adhesion as well as conformational changes of the bound protein. It is well accepted that proteins will bind more strongly to hydrophobic surfaces compared to hydrophilic surfaces; however, poor translation of these observations into in vivo outcomes have encouraged revised investigation into “ideal” properties such as, functional groups and wettability, and surface charge.

The most commonly explored functional groups are amino (–NH₂), carboxyl (–COOH), hydroxyl (–OH), and methyl (–CH₃) groups [273]. Of the hydrophilic surfaces, –NH₂ and –OH groups present positive and neutral charges, respectively, and have been reported to induce the highest infiltration of inflammatory cells in vivo [274–276] and thicker fibrotic capsules around the functionalised implant [276, 277]. However, in a study by Barbosa et al. (2006), implants functionalised with hydrophobic, neutral –CH₃ groups formed thicker capsules than –OH groups and also recruited higher numbers of Mac-1⁺ cells [278]. The authors suggested that, in their model, there was a directly proportional relationship between the severity of the acute inflammatory response and the thickness of the fibrotic capsule [278]. The implications of this simplistic model may not be translatable to all systems, and, in fact, there are contradictory reports on the ability of –CH₃ groups to promote cellular adhesion [274, 279, 280]. It is therefore important to recognise differences between in vitro and in vivo studies, which may account for this disparity.

4.2. Shaping and Tuning Innate Immune Effector Responses to Biomaterial Implants

The modification and derivatization of implant surfaces are being investigated to improve the biocompatibility of biomaterials. The ability to “mimick” the biology of the surrounding tissue or promote wound repair is thought to improve the integration of biomaterials and thus reduce the FBR [28, 270–272]. Despite successful attempts to redirect innate responses to constructive healing processes, materials such as alginate, collagen, intact, and decellularized ECM and ECM components are also susceptible to normal destructive tissue remodelling and unwanted metabolic breakdown products. Reproducing these materials may also be unfavourable for regulatory and manufacturing processes, and therefore synthetic polymers have been explored for surface coatings. One example of this is hydrogel coatings (PHEMA, PEG, and PVA), which become swollen with water, are highly permeable to analytes, and have mechanical properties akin to soft tissue. However, hydrogels and other synthetic polymers are limited in their adhesive abilities onto biomaterial scaffolds and, for this reason, are able to induce the FBR and, in some cases, are more likely to be degraded via macrophage and FBGC-mediated responses, ultimately leading to device failure. Therefore, two heavily investigated biomaterial modifications are alterations in surface chemistry and topography.

4.2.1. Surface Chemistry. The understanding that surface function alters protein adhesion and directs downstream cell recruitment has led to the global aim of producing “repellent” surfaces to moderate protein binding [273]. Methods of altering surface chemistry are vast but may be achieved by chemical grafting, self-assembled monolayers, or plasma polymerisation, and each has been tested for ultimately controlling the amount and composition of protein adhesion as well as conformational changes of the bound protein. It is well accepted that proteins will bind more strongly to hydrophobic surfaces compared to hydrophilic surfaces; however, poor translation of these observations into in vivo outcomes have encouraged revised investigation into “ideal” properties such as, functional groups and wettability, and surface charge.

The most commonly explored functional groups are amino (–NH₂), carboxyl (–COOH), hydroxyl (–OH), and methyl (–CH₃) groups [273]. Of the hydrophilic surfaces, –NH₂ and –OH groups present positive and neutral charges, respectively, and have been reported to induce the highest infiltration of inflammatory cells in vivo [274–276] and thicker fibrotic capsules around the functionalised implant [276, 277]. However, in a study by Barbosa et al. (2006), implants functionalised with hydrophobic, neutral –CH₃ groups formed thicker capsules than –OH groups and also recruited higher numbers of Mac-1⁺ cells [278]. The authors suggested that, in their model, there was a directly proportional relationship between the severity of the acute inflammatory response and the thickness of the fibrotic capsule [278]. The implications of this simplistic model may not be translatable to all systems, and, in fact, there are contradictory reports on the ability of –CH₃ groups to promote cellular adhesion [274, 279, 280]. It is therefore important to recognise differences between in vitro and in vivo studies, which may account for this disparity.

In the context of cell differentiation pathways, surfaces with –OH functionality show the highest capacity to induce osteoblast differentiation, followed by –NH₂ and –COOH, and the lowest capacity on –CH₃ surfaces [281, 282], although –CH₃ surfaces seemed to induce moderate myogenic differentiation [281]. Blocking antibodies revealed that cell differentiation was regulated by integrin binding [283] in alignment with observations of preferential focal adhesions formation on –OH > –NH₂ = –COOH > –CH₃ surfaces [282]. Focal adhesions are specialised regions of the cell that are rich in integrins and signalling molecules that allow attachment to the ECM and serve as signalling centres to regulate cell growth, survival, and gene expression [284]. Further evidence of focal adhesion dependence on surface chemistry was seen on –NH₂ surfaces that could regulate the expression of integrins and signalling molecules resulting in ERK1/2 activation in bone marrow stromal cells, which have osteogenic differentiation ability [285].

Not surprisingly, the differential involvement of integrin engagement coincides with the understanding of how adsorbed proteins can alter their conformation. Protein studies revealed that the ability to access fibronectin domains, integrin binding, and cell adhesion followed the order of –OH > –COOH = –NH₂ > –CH₃ surfaces [286, 287]. Interestingly, the complement component C3b can covalently link to OH [288, 289] and its inactive form, C3bi, is the receptor for Mac-1 [290], potentially offering an explanation for increased accumulation of CD11b⁺ cells (macrophages and neutrophils) at the implant site [291]. Interestingly, –COOH is recognised for imparting minimal inflammatory damage based on the observations that these hydrophilic and negatively charged surfaces have consistently thinner fibrotic capsules and reduce cell infiltrates at the implantation site [276, 278, 291]. Whilst repulsion of negatively charged cell membranes may account for some of these observations, the role of protein binding on these surfaces offers a more cohesive explanation. It has been found that hydrophobic surfaces including –CH₃ can more tightly bind proteins such as albumin [292, 293] and fibrinogen [293, 294] and cause conformational changes [292], whereas hydrophilic surfaces show faster protein desorption [295]. However, simple distinction of hydrophilicity is not sufficient to predict the protein binding kinetics of a given surface and, instead,
a second tier of differentiation by way of surface charge is required. Sivaraman et al. (2009) showed that proteins on –OH groups were able to retain their native structure to a much greater extent than any other functional group including the equivalently hydrophilic –COOH, which differs on the basis of its negative charge [292]. The authors suggested that the internal hydrophobic regions of a given protein are less likely to unfold in the presence of a hydrophilic surface and instead form hydrogen bonds with –OH groups via interactions of polar and charged amino acid residues presented on the protein surface. Interestingly, the observation that proteins adsorbed to –COOH surfaces showed greater structural rearrangement than their native forms was attributed to the negatively charged –COOH groups interacting with positively charged amino acid residues on the protein, perturbing the lowest free energy state of that protein, causing it to refold to the new lowest free energy state conformation. Similar observations and rationale were described for proteins on the hydrophobic and positively charged –NH₂ surfaces, resulting in greater conformational changes [292]. Together, protein binding kinetics and conformations on implant surfaces are dependent on surface chemistry and may contribute to explaining the FBR results in vivo.

4.2. Surface Topography. Methods of altering topography are wide and varied, including, but not limited to, particle deposition, self-assembled monolayers, soft photolithography, blasting, acid etching, and polymer expansion [296–298]. These techniques result in differential surface geometries in the micron and nanometre scale, producing “rough” surfaces based on protrusions, such as pillars, posts, gratings, and ridges, or dentations, such as pits and dots [104, 299–301]. Comparison of native substrates with modified topography is assessed by the functionality of cells that are of interest to the downstream application of the material, which may include osteoblasts in the case of bone implants but are mostly concerned with cells involved in the FBR. Interestingly, the notion of modulating surface “roughness” using micro and nanopatterns stems from the architectural understanding of homeostatic cell interactions with components of the ECM [302]. The ECM is a complex structure of intertwined pores, fibres, ridges, and protein bands in the nanoscale [303, 304]. The topographical control of cell interactions has inspired the investigation of synthetically produced disturbances for modulating implantation outcomes [302]. In general, “rougher” surfaces have shown altered cell adhesion [305–307], density and spreading [308, 309], modulated cytokine secretion [310, 311], motility [312, 313], enhanced proliferation and differentiation [308, 314], and macrophage fusion [104]; however these responses are cell-specific and dependent on the method of fabrication.

Additionally, surface roughness is further differentiated based on modified dimensions such as topography height, width, rigidity, and spacing and patterns. For example, Mohiuddin et al. (2012) used nanodots of various diameters to show that macrophage secretion of IL-6 was doubled on 50 nm nanodots compared to smooth surfaces but increased 3-fold on 200 nm nanodots. Interestingly, maximum cell spreading, focal adhesion, and cell density were seen on the 50 nm nanodots [301]. In a similar manner, Hulander et al. (2013) immobilised nanoparticles of different sizes and demonstrated that 56 nm particles decreased platelet activation; however the 36 nm particles allowed platelet contact with the “flattened” surface, inducing activation and cell flattening [306]. On the micron scale, Madden et al. (2010) revealed differences with pillars of different distances, where larger gratings, that is, 1 μm versus 250 nm distances, reduced macrophage fusion and cytokine secretion. Recently, differences in macrophage phenotype were shown to be regulated on surfaces anodised with 5 V or 20 V, where surfaces generated with 5 V caused macrophages to secret cytokines of an “M2” phenotype, whereas the rougher 20 V surfaces were associated with an M1 phenotype. Similar analysis of macrophage polarity has been described for porous versus nonporous poly(2-hydroxyethyl methacrylate-co-methacrylic acid) hydrogels showing that when compared to the nonporous hydrogels, implanted hydrogels with pores of 30–40 μm have greater neovascularisation and reduced fibrotic capsule [315]. Furthermore, porous hydrogels had a significant increase in the proportion of macrophages expressing macrophage mannose receptor (MMR) and a significant decrease in MMR⁺ cells, suggesting a phenotypic shift into an M2 phenotype [315]. These reports in conjugation with studies assessing macrophage polarity in the context of other scaffolds highlight the importance of a deeper analytical approach to immunophenotyping infiltrates and resolving proportional contributions of these cells towards signalling pathways and cytokine responses. Macrophage responses were assessed in a study by Bota et al. (2010) that used expanded polymers to create pores with different intranodal distances. The authors found that the largest distance of 4.4 μm produced the highest level of macrophage-derived IL-1β in vitro but, importantly, resulted in a thinner capsule surrounding implant in vivo [299]. The use of porous materials has been investigated for several decades and has been integrated into areas of orthopaedic implants, such as dental and bone (joint) implants. In general, the porous nature of these implants is ideal because they allow for tissue integration, vascularisation, and the transport of nutrients [316, 317]; however host responses can vary based on the scaffold material, pore size, and porosity. Although the ideal pore size for osteoblast functionality in implants for bone engineering is still disputed [318], pores ranging within 20–1500 μm [319] have been investigated for cell migration, proliferation, osteogenesis, and angiogenesis [320–322]. Importantly, the porosity and pore size must also be considered from the perspective of the implant’s mechanical properties to ensure that its strength is not comprised [318]. Collectively, disparity amongst various surface topographies highlights the importance of using cell types specific to a given implant function in order to assess the optimal properties that result in the desired response in vivo.

However, cellular responses are secondary to protein adsorption in an in vivo setting, and, for this reason, the effects of nanotopography on protein binding have also been investigated. Surface roughness was shown to increase serum protein adsorption by 70%; however inspection of specific proteins on these gold nanoparticle (58 nm) surfaces revealed
that the increase in protein was due to IgG antibody binding, whereas complement C3c decreased by 50% [323]. Further investigations have detailed the effect of nanotopography on altered adsorption and conformation of fibrinogen [324, 325] and fibronectin [326, 327], potentially accounting for differences in cell adhesion and activation on flat versus rough surfaces. It is suggested that alterations in protein binding are due to surface “curvature,” which can affect two main factors: (i) the orientation, unfolding or distances between adsorbed proteins, and (ii) distortion of the cytoskeleton upon membrane conformation on the shape of the curve [302, 328]. Together, these support the involvement of mechanotransduction as a mechanistic explanation for cell detection of surface topography. Mechanotransduction describes a process of how cells can relay a multitude of mechanical forces into the nucleus through the action of the cytoskeleton [329, 330]. It has been proposed that, in response to tension, cytoskeletal filaments reorient, causing the nucleus to distort and align against the axis of tension, potentially affecting nuclear scaffolds such as chromatin [331]. It has also been suggested that focal adhesions are the initiating site of mechanotransduction [332], offering an attractive rationale for topography-dependent cell response. In fact, several studies have shown surface-adherent cells can extend filopodia [333–335], which are finger-like protrusions of the cell membrane that are rich in actin and are found to contain integrins [336]. A study by Collie et al. (2011) used blocking antibodies to demonstrate a direct role for integrins in macrophages responses to topography, specifically showing that anti-β2 integrins abrogated IL-1β production, whereas blocking β1α,β3 integrins had no effect on macrophage responses [300].

The use of scanning electron microscopy has revealed unique cell behaviours on nanostructures [337] and provided insight into different forms of membrane contortion. Cells on patterned nanopillars have been shown to “bend” the pillars, most likely due to filopodia contraction; however, the ability to “tilt” these structures was dependent on the rigidity and stiffness of the material [338]. In some cases, cells attempted to phagocytose nanostructures, potentially utilising the increased surface area to promote greater points of contact for “grip” [308, 339]. Interestingly, it was recently observed that nanostructures could penetrate fibroblasts, which the authors suspected to be due to failed phagocytosis, resulting in cell thinning and membrane rupture [339]. Together, these studies highlight how the multitude of techniques and topography can differentially affect cell responses.

4.3. Modulating Inflammasome Components by Biomaterial Surface Properties. The goal of shaping innate effector immune cell responses within FBR pathways has been investigated in many different contexts from alternating biomaterial surface properties through to inhibiting innate effector cell outputs. However, how surface characteristics can manipulate innate effector cell signalling pathways requires further investigation. Currently, the MATS model is the most plausible hypothesis available. It has been demonstrated that membrane curvature as a result of cytoskeletal changes can reorganise local lipid composition and expose hydrophobic cavities [340–342]. This may in fact support the independent observations documented by Malik et al. (2011) that suggested a role of cholesterol and Syk in macrophage-derived IL-1β when in the presence of PMMA microspheres [264]. More recently, surface contact between macrophages and MSU crystals was shown to be sufficient to cause IL-1β secretion in vitro via the NLRP3 inflammasome. The authors demonstrated that the release of IL-1β upon MSU crystal contact was a result of K+ efflux, offering an additional mechanism that may result from membrane perturbations. It is known that K+ efflux is one model of NLRP3 activation and was recently found to be the common outcome amongst NLRP3 stimuli [343]. Therefore, the notion that surface receptor-independent signalling can be initiated upon changes to membrane curvature opens the possibility of assessing how surface topography can be used to modulate these responses. In this way, biomaterial-adherent cells may conform their membrane to the curvature of the surface topography, which may result in membrane lipid sorting and Syk kinase activation and the opening of ion channels to permit signalling, as well as inducing mechanosensing pathways, in a concerted manner that activates the innate effector cell.

The physicality of cell membrane conformations on various topographies is not to overlook the potential role of surface chemistry in controlling innate effector cell responses at a molecular level. Unfortunately, studies that assess the signalling pathways within biomaterial-adherent cells on various chemistries are minimal. A recent report comparing two zwitterionic hydrogels demonstrated that, when compared to poly(2-hydroxyethyl methacrylate) (PHEMA) hydrogels, polycarboxybetaine methacrylate (PCBMA) hydrogels induced less inflammation in vitro, thinner fibrotic capsule at 4 weeks and 3 months after implantation and supported vascularisation and more macrophages with anti-inflammatory phenotypes in vivo [344]. Importantly, this study demonstrated that changes to inflammatory responses were a result of the hydrogel chemistry and not due to endotoxin contamination, a fact that many other studies often neglect to mention or do not test for. The authors propose that PCBMA hydrogels were superior to PHEMA because they could resist protein adsorption to a greater extent, thereby reducing recognition by innate effector cells, namely, macrophages [344]. This then raises the argument that innate effector cell modulation could be achieved indirectly by controlling protein adsorption to eliminate receptor-mediated signalling. How this may in turn affect inflammasome activation is not yet determined and will require extensive investigations both in vitro and in vivo. There are many considerations to account for prior to translating preclinical therapeutic interventions into strategies for humans. A single approach may not adequately address clinical complications, and for this reason targeting different facets of the FBR may improve patient outcomes, whereby surface modification would alter protein adsorption and acute cell infiltration, allowing a more manageable inflammatory response for the administration of innate cell-targeted therapies.
5. Future Directions

As the field of biomaterials becomes infiltrated with the medical and biological sciences, it is evident that a deep and mechanistic understanding of immunological responses to implants is at the forefront of biocompatibility and tissue integration. In order to implement rationally designed implantable biomaterials, it is necessary to quantify the full breadth and temporal allocation of immune responses that contribute to downstream FBR events such as fibrotic encapsulation and biomaterial rejection [345]. Whilst in vitro methods are important for selecting materials and designs that may hold promise, the use of culture based techniques limits the full understanding of complex immune interactions. To this end the development of more robust and predictive in vivo models of biomaterial-induced inflammation is required for use with the appropriate genetically modified strains of mice deficient in key innate immune effector response pathways to ultimately assess the effect of physicochemical surface modifications on the initiation and progression of the FBR. It is important to gain a detailed understanding of the innate immune inflammatory processes by which neutrophils and monocytes/macrophages can be activated by biomaterial surfaces in the absence of any specific cell surface receptor or cytosolic receptor signalling. Furthermore, there is potential for exploring whether ASC-mediated inflammasome assembly is an important driver of the FBR and whether the surface nanotopography and the chemical reactive potential of an implant can modulate these responses. The relationship between how the physical characteristics of the surface of a biomaterial implant can affect inflammasome-dependent FBR initiation and progression will be mechanistically resolved using genetically modified mice made deficient in the key signalling pathways that are predicted to be the major arbiters in how this occurs and will also allow definition of the rules by which biomaterial surface nanotopography and chemical reactive potential change how the FBR is initiated and progresses.

6. Conclusions

The biggest challenge in the field of biomaterials is the understanding and, importantly, the prediction of long-term biological responses in patients receiving implantable biomaterials [29]. Deconstructing and detailing these mechanisms will allow for more targeted approaches and highlights how immune processes are amenable to manipulation by synthetic biomaterials. We anticipate that future explorations in this field of research will ultimately facilitate rationally designed and manufactured biomedical implants with substrate surface characteristics that will enhance utility, function, and clinical application.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

[1] A. H. Morris and T. R. Kyriakides, “Matricellular proteins and biomaterials,” Matrix Biology, vol. 37, pp. 183–191, 2014.
[2] P. Agrawal, S. Soni, G. Mittal, and A. Bhatnagar, “Role of polymeric biomaterials as wound healing agents,” The International Journal of Lower Extremity Wounds, vol. 13, no. 3, pp. 180–190, 2014.
[3] O. Peralta, S. Diaz, and H. Croxatto, “Subdermal contraceptive implants,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 53, no. 1–6, pp. 223–226, 1995.
[4] A. M. Teunissen, B. Grimm, and F. J. M. E. Roumen, “Continuation rates of the subdermal contraceptive Implanon and associated influencing factors,” The European Journal of Contraception & Reproductive Health Care, vol. 19, no. 1, pp. 15–21, 2014.
[5] L. D. Ireland, V. Goyal, C. A. Raker, A. Murray, and R. H. Allen, “The effect of immediate postpartum compared to delayed postpartum and interval etonogestrel contraceptive implant insertion on removal rates for bleeding,” Contraception, vol. 90, no. 3, pp. 253–258, 2014.
[6] I. Babiak, “Open tibial fractures grade IIIC treated successfully with external fixation, negative-pressure wound therapy and recombinant human bone morphogenetic protein 7,” International Wound Journal, vol. 11, no. 5, pp. 476–482, 2014.
[7] E. Bar-On, T. Becker, K. Katz, S. Velkes, M. Salai, and D. M. Weigl, “Corrective lower limb osteotomies in children using temporary external fixation and percutaneous locking plates,” Journal of Children’s Orthopaedics, vol. 3, no. 2, pp. 137–143, 2009.
[8] G. G. Zafiropoulos, O. Hoffmann, and G. Deli, “A method for fabrication of implant-supported fixed partial dentures,” The Journal of Oral Implantology, vol. 40, no. 3, pp. 271–279, 2014.
[9] V. Wiegering, S. Schmid, O. Andres et al., “Thrombosis as a complication of central venous access in pediatric patients with malignancies: a 5-year single-center experience,” BMC Hematology, vol. 14, no. 1, p. 18, 2014.
[10] S. H. Han and J. H. Lee, “Colonic stent-related complications and their management,” Clinical Endoscopy, vol. 47, no. 5, pp. 415–419, 2014.
[11] T. H. Park, S. W. Seo, J.-K. Kim, and C. H. Chang, “Clinical experience with polymethylmethacrylate microsphere filler complications,” Aesthetic Plastic Surgery, vol. 36, no. 2, pp. 421–426, 2012.
[12] K. C. Smith, “Reversible vs. nonreversible fillers in facial aesthetics: concerns and considerations,” Dermatology Online Journal, vol. 14, no. 8, article 3, 2008.
[13] J. Charnley, “Anchorage of the femoral head prosthesis to the shaft of the femur,” The Journal of Bone and Joint Surgery—British Volume, vol. 42, pp. 28–30, 1960.
[14] M. Marcolongo, P. Ducheyne, J. Garino, and E. Schepers, “Bioactive glass fiber/polymeric composites bond to bone tissue,” Journal of Biomedical Materials Research, vol. 39, no. 1, pp. 161–170, 1997.
[15] W. Holand, M. Schweiger, R. Watzke, A. Peschke, and H. Kappert, “Ceramics as biomaterials for dental restoration,” Expert Review of Medical Devices, vol. 5, no. 6, pp. 729–745, 2008.
[16] P. Kosyfaki and M. V. Swain, “Adhesion determination of dental porcelain to zirconia using the Schwickertah test: strength vs. fracture energy approach,” Acta Biomaterialia, vol. 10, no. 11, pp. 4861–4869, 2014.
[17] G. Lorenzoni, F. Folino, N. Soriani, S. Iliceto, and D. Gregori, “Cost-effectiveness of early detection of atrial fibrillation via
remote control of implanted devices,” *Journal of Evaluation in Clinical Practice*, vol. 20, no. 5, pp. 570–577, 2014.

[18] M. E. McVor, J. Reddinger, E. Floden et al., “Study of pacemaker and implantable cardioverter defibrillator triggering by electronic article surveillance devices (SPICED TEAS),” *Pacing and Clinical Electrophysiology*, vol. 21, no. 10, pp. 1847–1861, 1998.

[19] R. Gifford, M. M. Batchelor, Y. Lee, G. Gokulrangan, M. E. Meyerhoff, and G. S. Wilson, “Mediation of in vivo glucose sensor inflammatory response via nitric oxide release,” *Journal of Biomedical Materials Research Part A*, vol. 75, no. 4, pp. 755–766, 2005.

[20] P. A. Palod, S. S. Pandey, S. Hayase, and V. Singh, “Template-assisted electrochemical growth of poly(pyrrrole) nanotubes for development of high sensitivity glucose biosensor,” *Applied Biochemistry and Biotechnology*, vol. 174, no. 3, pp. 1059–1072, 2014.

[21] N. N. Le, M. B. Rose, H. Levinson, and B. Klitzman, “Implant healing in experimental animal models of diabetes,” *Journal of Diabetes Science and Technology*, vol. 5, no. 3, pp. 605–618, 2011.

[22] S. Franz, S. Rammelt, D. Scharnweber, and J. C. Simon, “Immune responses to implants—a review of the implications for the design of immunomodulatory biomaterials,” *Biomaterials*, vol. 32, no. 28, pp. 6692–6709, 2011.

[23] S. K. Chuang, L. J. Wei, C. W. Douglass, and T. B. Dodson, “Risk factors for dental implant failure: a strategy for the analysis of clustered failure-time observations,” *Journal of Dental Research*, vol. 81, no. 8, pp. 572–577, 2002.

[24] B. R. Chrcanovic, T. Albrektsson, and A. Wennerberg, “Reasons for failures of oral implants,” *Journal of Oral Rehabilitation*, vol. 41, no. 6, pp. 443–476, 2014.

[25] B. R. Chrcanovic, T. Albrektsson, and A. Wennerberg, “Periodontally compromised vs. periodontally healthy patients and dental implants: a systematic review and meta-analysis,” *Journal of Dentistry*, vol. 42, no. 12, pp. 1509–1527, 2014.

[26] J. M. Anderson, “Inflammatory response to implants,” *ASAIO Transactions*, vol. 34, no. 2, pp. 101–107, 1988.

[27] B. N. Brown and S. F. Badyak, “Expanded applications, shifting paradigms and an improved understanding of host-biomaterial interactions,” *Acta Biomaterialia*, vol. 9, no. 2, pp. 4948–4955, 2013.

[28] F. Boccafoschi, C. Mosca, and M. Cannas, “Cardiovascular biomaterials: when the inflammatory response helps to efficiently restore tissue functionality?” *Journal of Tissue Engineering and Regenerative Medicine*, vol. 8, no. 4, pp. 253–267, 2014.

[29] W. K. Ward, “A review of the foreign-body response to subcutaneously-implanted devices: the role of macrophages and cytokines in biofouling and fibrosis,” *Journal of Diabetes Science and Technology*, vol. 2, no. 5, pp. 768–777, 2008.

[30] J. M. Anderson, A. Rodriguez, and D. T. Chang, “Foreign body reaction to biomaterials,” *Seminars in Immunology*, vol. 20, no. 2, pp. 86–100, 2008.

[31] R. E. Baier and R. C. Dutton, “Initial events in interactions of blood with a foreign surface,” *Journal of Biomedical Materials Research*, vol. 3, no. 1, pp. 191–206, 1969.

[32] L. Vroman, A. L. Adams, G. C. Fischer, and P. C. Munoz, “Interaction of high molecular weight kininogen, factor XII, and fibrinogen in plasma at interfaces,” *Blood*, vol. 55, no. 1, pp. 156–159, 1980.

[33] C. J. Wilson, R. E. Clegg, D. I. Leavesley, and M. J. Pearcy, “Mediation of biomaterial-cell interactions by adsorbed proteins: a review,” *Tissue Engineering*, vol. II, no. 1-2, pp. 1–18, 2005.

[34] G. Nimeri, B. Lassen, C. G. Gölander, U. Nilsson, and H. Elwing, “Adsorption of fibrinogen and some other proteins from blood plasma at a variety of solid surfaces,” *Journal of Biomaterials Science. Polymer Edition*, vol. 6, no. 6, pp. 573–583, 1994.

[35] C. J. Nonckremalan, S. Fleith, P. G. Rouxhet, and C. C. DuPont-Gillain, “Competitive adsorption of fibrinogen and albumin and blood platelet adhesion on surfaces modified with nanoparticles and/or PEO,” *Colloids and Surfaces B: Biointerfaces*, vol. 77, no. 2, pp. 139–149, 2010.

[36] D. J. Fabriziuz-Homan and S. L. Cooper, “Competitive adsorption of vitronectin with albumin, fibrinogen, and fibronectin on polymeric biomaterials,” *Journal of Biomedical Materials Research*, vol. 25, no. 8, pp. 953–971, 1991.

[37] D. J. Fabriziuz-Homan and S. L. Cooper, “A comparison of the adsorption of three adhesive proteins to biomaterial surfaces,” *Journal of Biomaterials Science. Polymer Edition*, vol. 3, no. 1, pp. 27–47, 1991.

[38] M. B. Gorbet and M. V. Sefton, “Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes,” *Biomaterials*, vol. 25, no. 26, pp. 5681–5703, 2004.

[39] K. N. Ekdahl, J. D. Lambris, H. Elwing et al., “Innate immunity activation on biomaterial surfaces: a mechanistic model and coping strategies,” *Advanced Drug Delivery Reviews*, vol. 63, no. 12, pp. 1042–1050, 2011.

[40] B. Nilsson, K. N. Ekdahl, T. E. Mollnes, and J. D. Lambris, “The role of complement in biomaterial-induced inflammation,” *Molecular Immunology*, vol. 44, no. 1–3, pp. 82–94, 2007.

[41] J. Andersson, K. N. Ekdahl, J. D. Lambris, and B. Nilsson, “Binding of C3 fragments on top of adsorbed plasma proteins during complement activation on a model biomaterial surface,” *Biomaterials*, vol. 26, no. 13, pp. 1477–1485, 2005.

[42] B. Engelmann and S. Massberg, “Thrombosis as an intravascular effector of innate immunity,” *Nature Reviews Immunology*, vol. 13, no. 1, pp. 34–45, 2013.

[43] Y. Wu, F. I. Simonovsky, B. D. Ratner, and T. A. Horbett, “The role of adsorbed fibrinogen in platelet adhesion to polyurethane surfaces: a comparison of surface hydrophobicity, protein adsorption, monoclonal antibody binding, and platelet adhesion,” *Journal of Biomedical Materials Research Part A*, vol. 74, no. 4, pp. 722–738, 2005.

[44] A. Chiumiento, S. Lamponi, and R. Barbucci, “Role of fibrinogen conformation in platelet adhesion activation,” Biomacromolecules, vol. 8, no. 2, pp. 523–531, 2007.

[45] F. M. Szaba and S. T. Smiley, “Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo,” *Blood*, vol. 99, no. 3, pp. 1053–1059, 2002.

[46] M. J. Flick, X. Du, D. P. Witte et al., “Leukocyte engagement of fibrin(ogen) via the integrin receptor αMβ2/Mac-1 is critical for host inflammatory response in vivo,” *The Journal of Clinical Investigation*, vol. 113, no. 11, pp. 1596–1606, 2004.

[47] A. K. McNally, J. A. Jones, S. R. MacEwan, E. Colton, and J. M. Anderson, “Vıtronectin is a critical protein adhesion substrate for IL-4–induced foreign body giant cell formation,” *Journal of Biomedical Materials Research—Part A*, vol. 86, no. 2, pp. 535–543, 2008.

[48] C. R. Jenney and J. M. Anderson, “Adsorbed serum proteins responsible for surface dependent human macrophage behavior,” *Journal of Biomedical Materials Research*, vol. 49, no. 4, pp. 435–447, 2000.

[49] T. Groth, I. Zlatanov, and G. Altankov, “Adhesion of human peripheral lymphocytes on biomaterials preadsorbed with...
[79] N. Kanbe, M. Kurosawa, T. Yamashita, F. Kurimoto, Y. Nagaihara, and Y. Miyachi, “Cord-blood-derived human cultured mast cells produce interleukin 13 in the presence of stem cell factor,” *International Archives of Allergy and Immunology*, vol. 119, no. 2, pp. 138–142, 1999.

[80] R. Rezani, L. Rodella, G. M. Tartaglia, C. Paganelli, P. Sapelli, and R. Bianchi, “Mast cells and the inflammatory response to different implanted biomaterials,” *Archives of Histology and Cytology*, vol. 67, no. 3, pp. 211–217, 2004.

[81] L. Tak, T. A. Jennings, and J. W. Eaton, “Mast cells mediate acute inflammatory responses to implanted biomaterials,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 95, no. 15, pp. 8841–8846, 1998.

[82] L. Christenson, L. Wahlberg, and P. Aebischer, “Mast cells and tissue reaction to intraperitoneally implanted polymer capsules,” *Journal of Biomedical Materials Research*, vol. 25, no. 9, pp. 1119–1131, 1991.

[83] N. Kanbe, M. Kurosawa, H. Nagata, H. Saitoh, and Y. Miyachi, “Cord blood-derived human cultured mast cells produce transforming growth factor beta1,” *Clinical and Experimental Allergy*, vol. 29, no. 1, pp. 105–113, 1999.

[84] F. Levi-Schaffer, K. F. Austen, P. M. Gravallese, and R. L. Stevens, “Coculture of interleukin 3-dependent mouse mast cells with fibroblasts results in a phenotypic change of the mast cells,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 83, no. 17, pp. 6485–6488, 1986.

[85] E. T. Dayton, P. Pharr, M. Ogawa et al., “3T3 fibroblasts induce cloned interleukin 3-dependent mouse mast cells to resemble connective tissue mast cells in granular constituency,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 85, no. 2, pp. 569–572, 1988.

[86] T. Nakayama, L. Yao, and G. Tosato, “Mast cell-derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors,” *The Journal of Clinical Investigation*, vol. 114, no. 9, pp. 1317–1325, 2004.

[87] W. R. Roche, “Mast cells and tumour angiogenesis: the tumour-mediated release of an endothelial growth factor from mast cells,” *International Journal of Cancer*, vol. 36, no. 6, pp. 721–728, 1985.

[88] D. Ribatti and E. Crivellato, “Mast cells, angiogenesis, and tumour growth,” *Biochimica et Biophysica Acta*, vol. 1822, no. 1, pp. 2–8, 2012.

[89] J. Yang, B. Jao, A. K. McNally, and J. M. Anderson, “In vivo quantitative and qualitative assessment of foreign body giant cell formation on biomaterials in mice deficient in natural killer lymphocyte subsets, mast cells, or the interleukin-4 receptor and in severe combined immunodeficient mice,” *Journal of Biomedical Materials Research. Part A*, vol. 102, no. 6, pp. 2017–2023, 2014.

[90] A. Rodriguez, S. R. MacEwan, H. Meyerson, J. T. Kirk, and J. M. Anderson, “The foreign body reaction in T-cell-deficient mice,” *Journal of Biomedical Materials Research—Part A*, vol. 90, no. 1, pp. 106–113, 2009.

[91] S. Goodman, J.-S. Wang, D. Regula, and P. Aspenberg, “T-lymphocytes are not necessary for particulate polyethylene-induced macrophage recruitment: histologic studies of the rat tibia,” *Acta Orthopaedica*, vol. 65, no. 2, pp. 157–160, 1994.

[92] M. Yokoyama, T. Nakahashi, T. Nishimura et al., “Adhesion behavior of rat lymphocytes to poly(ether)-poly(amine acid) block and graft copolymers,” *Journal of Biomedical Materials Research*, vol. 20, no. 7, pp. 867–878, 1986.

[93] A. Rodriguez, G. Voskerician, H. Meyerson, S. R. MacEwan, and J. M. Anderson, “T cell subset distributions following primary and secondary implantation at subcutaneous biomaterial implant sites,” *Journal of Biomedical Materials Research Part A*, vol. 85, no. 2, pp. 556–565, 2008.

[94] J. M. Curtisinger, C. S. Schmidt, A. Mondino et al., “Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells,” *Journal of Immunology*, vol. 162, no. 6, pp. 3256–3262, 1999.

[95] A. Rodriguez and J. M. Anderson, “Evaluation of clinical biomaterial surface effects on T lymphocyte activation,” *Journal of Biomedical Materials Research—Part A*, vol. 92, no. 1, pp. 214–220, 2010.

[96] J. E. Smith-Garvin, G. A. Koretzky, and M. S. Jordan, “T cell activation,” *Annual Review of Immunology*, vol. 27, pp. 591–619, 2009.

[97] W. G. Brodbeck, M. MacEwan, E. Colton, H. Meyerson, and J. M. Anderson, “Lymphocytes and the foreign body response: lymphocyte enhancement of macrophage adhesion and fusion,” *Journal of Biomedical Materials Research Part A*, vol. 74, no. 2, pp. 222–229, 2005.

[98] D. T. Chang, E. Colton, and J. M. Anderson, “Paracrine and juxtacrine lymphocyte enhancement of adherent macrophage and foreign body giant cell activation,” *Journal of Biomedical Materials Research Part A*, vol. 89, no. 2, pp. 490–498, 2009.

[99] D. T. Chang, J. A. Jones, H. Meyerson et al., “Lymphocyte/macrophage interactions: biomaterial surface-dependent cytokine, chemokine, and matrix protein production,” *Journal of Biomedical Materials Research. Part A*, vol. 87, no. 3, pp. 676–687, 2008.

[100] D. W. Grainger, “All charged up about implanted biomaterials,” *Nature Biotechnology*, vol. 31, no. 6, pp. 507–509, 2013.

[101] E.-C. Shen, T.-C. Chou, C.-H. Gau, H.-P. Tu, Y.-T. Chen, and E. Fu, “Releasing growth factors from activated human platelets after chitosan stimulation: a possible bio-material for platelet-rich plasma preparation,” *Clinical Oral Implants Research*, vol. 17, no. 5, pp. 572–578, 2006.

[102] R. J. Pitsch, D. J. Minion, M. L. Goman, J. A. van Aalst, P. L. Fox, and L. M. Graham, “Platelet-derived growth factor production by cells from Dacron grafts implanted in a canine model,” *Journal of Vascular Surgery*, vol. 26, no. 1, pp. 70–78, 1997.

[103] S. S. Jensen, N. Broggini, G. Weibrich, E. Hjorting-Hansen, R. Schen, and D. Buser, “Bone regeneration in standardized bone defects with autografts or bone substitutes in combination with platelet concentrate: a histologic and histomorphometric study in the mandibles of minipigs,” *International Journal of Oral and Maxillofacial Implants*, vol. 20, no. 5, pp. 703–712, 2005.

[104] S. Chen, J. A. Jones, Y. Xu, H.-Y. Low, J. M. Anderson, and K. W. Leong, “Characterization of topographical effects on macrophage behavior in a foreign body response model,” *Biomaterials*, vol. 31, no. 13, pp. 3479–3491, 2010.

[105] P. Bao, A. Kodra, M. Tomic-Canic, M. S. Golinko, H. P. Ehrlich, and H. Brem, “The role of vascular endothelial growth factor in wound healing,” *The Journal of Surgical Research*, vol. 153, no. 2, pp. 347–358, 2009.

[106] K. Garg, S. A. Sell, P. Madurantakam, and G. L. Bowlin, “Angiogenic potential of human macrophages on electrospun biodegradable vascular grafts,” *Biomedical Materials*, vol. 4, no. 3, Article ID 031001, 2009.
E$_1$ by osteoblast-like cells cultured on titanium surfaces blasted with TiO$_2$ particles,” Clinical Oral Implants Research, vol. 14, no. 1, pp. 50–56, 2003.

[108] R. F. Diegelmann and M. C. Evans, "Wound healing: an overview of acute, fibrotic and delayed healing," Frontiers in Bioscience, vol. 9, pp. 283–289, 2004.

[109] P. R. Castro, S. M. Marques, P. P. Campos et al., "Kinetics of implant-induced inflammatory angiogenesis in abdominal muscle wall in mice," Microvascular Research, vol. 84, no. 1, pp. 9–15, 2012.

[110] T. Oviedo-Socarrás, A. C. Vasconcelos, I. X. Barbosa, N. B. Pereira, P. P. Campos, and S. P. Andrade, "Diabetes alters inflammation, angiogenesis, and fibrogenesis in intraperitoneal implants in rats," Microvascular Research, vol. 93, pp. 23–29, 2014.

[111] R. O. Hynes, "The extracellular matrix: not just pretty fibrils," Science, vol. 326, no. 5957, pp. 1216–1219, 2009.

[112] A. R. de Fougerolles and V. E. Kotéliansky, "Regulation of monocyte gene expression by the extracellular matrix and its functional implications," Immunological Reviews, vol. 186, pp. 208–220, 2002.

[113] B. D. Ratner and S. J. Bryant, "Biomaterials: where we have been and where we are going," Annual Review of Biomedical Engineering, vol. 6, pp. 41–75, 2004.

[114] B. D. Ratner, "Reducing capsular thickness and enhancing angiogenesis around implant drug release systems," Journal of Controlled Release, vol. 78, no. 1–3, pp. 211–218, 2002.

[115] S. Akira, S. Uematsu, and O. Takeuchi, "Pathogen recognition and innate immunity," Cell, vol. 124, no. 4, pp. 783–801, 2006.

[116] J. J. Oppenheim, P. Tewary, G. De La Rosa, and D. Yang, "Alarmins initiate host defense," Advances in Experimental Medicine and Biology, vol. 601, pp. 185–194, 2007.

[117] D. Yang, F. Wei, P. Tewary, O. M. Z. Howard, and J. J. Oppenheim, "Alarmin-induced cell migration," European Journal of Immunology, vol. 43, no. 6, pp. 1412–1418, 2013.

[118] M. E. Bianchi, "DAMPs, PAMPs and alarmins: all we need to know about danger," Journal of Leukocyte Biology, vol. 81, no. 1, pp. 1–5, 2007.

[119] K. R. Diener, N. Al-Dasooqi, E. L. Lousberg, and J. D. Hayball, "The multifunctional alarm HMGB1 with roles in the pathophysiology of sepsis and cancer," Immunology and Cell Biology, vol. 91, no. 7, pp. 443–450, 2013.

[120] M. E. Bianchi, M. Beltrame, and G. Paonezza, "Specific recognition of cruciform DNA by nuclear protein HMGI\(_c\)," Science, vol. 243, no. 4894, pp. 1056–1059, 1989.

[121] M. E. Bianchi and M. Beltrame, "Flexing DNA: HMG-box proteins and their partners," The American Journal of Human Genetics, vol. 63, no. 6, pp. 1573–1577, 1998.

[122] H. Wang, O. Bloom, M. Zhang et al., "HMGB-1 as a late mediator of endotoxin lethality in mice," Science, vol. 285, no. 5425, pp. 248–251, 1999.

[123] L.-C. Li, J. Gao, and J. Li, "Emerging role of HMGB1 in fibrotic diseases," Journal of Cellular and Molecular Medicine, vol. 18, no. 12, pp. 2331–2339, 2014.

[124] P. Scaffidi, T. Misteli, and M. E. Bianchi, "Release of chromatin protein HMGB1 by necrotic cells triggers inflammation," Nature, vol. 418, no. 6894, pp. 191–195, 2002.

[125] I. E. Dumitriu, P. Baruah, B. Valentinis et al., "Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products," Journal of Immunology, vol. 174, no. 12, pp. 7506–7515, 2005.

[126] S.-A. Lee, M. S. Kwak, S. Kim, and J.-S. Shin, "The role of high mobility group box 1 in innate immunity," Yonsei Medical Journal, vol. 55, no. 3, pp. 1165–1176, 2014.

[127] L. Campana, L. Bosurgi, M. E. Bianchi, A. A. Manfredi, and P. Rovere-Querini, "Requirement of HMGB1 for stromal cell-derived factor-1/CXCL12-dependent migration of macrophages and dendritic cells," Journal of Leukocyte Biology, vol. 86, no. 3, pp. 609–615, 2009.

[128] A. Rouhiainen, J. Kuja-Panula, E. Wilkman et al., "Regulation of monocyte migration by amphoterin (HMGB1)," Blood, vol. 104, no. 4, pp. 1174–1182, 2004.

[129] N. Maugeri, P. Rovere-Querini, M. Baldini et al., "Oxidative stress elicits platelet/HMGB1 interactions in microvascular inflammation through HMGB1: a Candidate for microvessel injury in systemic sclerosis," Antioxidants & Redox Signaling, vol. 20, no. 7, pp. 1060–1074, 2014.

[130] L. M. Ayer, J.-L. Senecal, L. Martin, G. H. Dixon, and M. J. Fritzler, "Antibodies to high mobility group proteins in systemic sclerosis," Journal of Rheumatology, vol. 21, no. 11, pp. 2071–2075, 1994.

[131] S. M. Rowe, P. L. Jackson, G. Liu et al., "Potential role of high-mobility group box 1 in cystic fibrosis airway disease," American Journal of Respiratory and Critical Care Medicine, vol. 178, no. 8, pp. 822–831, 2008.

[132] M. Entezari, D. J. Weiss, R. Sitapara et al., "Inhibition of high-mobility group box 1 protein (HMGB1) enhances bacterial clearance and protects against Pseudomonas Aeruginosa pneumonia in cystic fibrosis," Molecular Medicine, vol. 18, no. 1, pp. 477–485, 2012.

[133] W.-S. Ge, J.-X. Wu, J.-G. Fan, Y.-W. Wang, and Y.-W. Chen, "Inhibition of high-mobility group box 1 expression by siRNA in rat hepatic stellate cells," World Journal of Gastroenterology, vol. 17, no. 36, pp. 4090–4098, 2011.

[134] M. Ebina, H. Taniguchi, T. Miyasho et al., "Gradual increase of high mobility group protein B1 in the lungs after the onset of acute exacerbation of idiopathic pulmonary fibrosis," Pulmonary Medicine, vol. 2011, Article ID 916486, pp. 9, 2011.

[135] N. Hamada, T. Maeyama, T. Kawaguchi et al., "The role of high-mobility group box 1 protein in pulmonary fibrosis," American Journal of Respiratory Cell and Molecular Biology, vol. 39, no. 4, pp. 440–447, 2008.

[136] A. Chitanuwat, N. Laorsisin, and N. Dhanesuan, "Role of HMGB1 in proliferation and migration of human gingival and periodontal ligament fibroblasts," Journal of Oral Science, vol. 55, no. 1, pp. 45–50, 2013.

[137] Q. Zhang, S. O’Hearn, S. L. Kavalukas, and A. Barbul, "Role of HMGB1 in wound healing," The Journal of Surgical Research, vol. 176, no. 1, pp. 343–347, 2012.

[138] C. Hou, J. Kong, Y. Liang et al., "HMGB1 contributes to allergen-induced airway remodeling in a murine model of chronic asthma by modulating airway inflammation and activating lung fibroblasts," Cellular & Molecular Immunology, 2014.

[139] E. Ranzato, M. Patrone, M. Pedrazzi, and B. Burlando, "Hmgb1 promotes wound healing of 3T3 mouse fibroblasts via RAGE-dependent ERK1/2 activation," Cell Biochemistry and Biophysics, vol. 57, no. 1, pp. 9–17, 2010.

[140] H. Wåhåmaa, H. Schierbeck, H. S. Hreggvidsdottir et al., "High mobility group box protein 1 in complex with lipopolysaccharide or LPS promotes an increased inflammatory phenotype in synovial fibroblasts," Arthritis Research & Therapy, vol. 13, no. 4, article R136, 2011.
A. Abe, T. Kuwata, C. Yamauchi, Y. Higuchi, and A. Ochiai, “High Mobility Group Box1 (HMGBox1) released from cancer cells induces the expression of pro-inflammatory cytokines in peritoneal fibroblasts,” *Pathology International*, vol. 64, no. 6, pp. 267–275, 2014.

J. E. Babensee, “Interaction of dendritic cells with biomaterials,” *Seminars in Immunology*, vol. 20, no. 2, pp. 101–108, 2008.

A. L. Rankin, J. B. Mumm, E. Murphy et al., “IL-33 induces IL-13-dependent cutaneous fibrosis,” *Journal of Immunology*, vol. 184, no. 3, pp. 1526–1535, 2010.

L. R. Lopetuso, F. Scaldaferri, and T. T. Pizarro, “Emerging role of the interleukin (IL)-33/ST2 axis in gut mucosal wound healing and fibrosis,” *Fibrogenesis & Tissue Repair*, vol. 5, no. 1, article 18, 2012.

Q. Gao, Y. Li, and M. Li, “The potential role of IL-33/ST2 signaling in fibrotic diseases,” *Journal of Leukocyte Biology*, 2015.

P. Marvie, M. Lisbonne, A. L’Helgoualc’h et al., “Interleukin-33 overexpression is associated with liver fibrosis in mice and humans,” *Journal of Cellular and Molecular Medicine*, vol. 14, no. 6, pp. 1726–1739, 2010.

I. G. Luzina, P. Kopach, V. Lockatell et al., “Interleukin-33 potentiates bleomycin-induced lung injury,” *American Journal of Respiratory Cell and Molecular Biology*, vol. 49, no. 6, pp. 999–1008, 2013.

T. McHedlidze, M. Waldnner, S. Zopf et al., “Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis,” *Immunity*, vol. 39, no. 2, pp. 357–371, 2013.

E. Lefrançais and C. Cayrol, “Mechanisms of IL-33 processing and secretion: differences and similarities between IL-1 family members,” *European Cytokine Network*, vol. 23, no. 4, pp. 120–127, 2012.

E. Lefrançais, S. Roga, V. Gautier et al., “IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 109, no. 5, pp. 1673–1678, 2012.

M. Komai-Koma, D. Xu, Y. Li, A. N. J. McKenzie, I. B. McInnes, and F. Y. Liew, “IL-33 is a chemoattractant for human TH2 cells,” *European Journal of Immunology*, vol. 37, no. 10, pp. 2779–2786, 2007.

M. D. Smithgall, M. R. Comeau, B.-R. Park Yoon, D. Kaufman, R. Armitage, and D. E. Smith, “IL-33 amplifies both T\(\alpha1\)- and T\(\beta1\)-2-type responses through its activity on human basophils, allergen-reactive T\(\beta1\)2 cells, iNKT and NK Cells,” *European Journal of Immunology*, vol. 20, no. 8, pp. 1019–1030, 2008.

J. Schmitz, A. Owyang, E. Oldham et al., “IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines,” *Immunity*, vol. 23, no. 5, pp. 479–490, 2005.

D. Li, R. Guabiraba, A.-G. Besnard et al., “IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice,” *The Journal of Allergy and Clinical Immunology*, vol. 134, no. 6, pp. 1422–1432, 2014.

R. O. Hynes, “Integrins: versatility, modulation, and signaling in cell adhesion,” *Cell*, vol. 69, no. 1, pp. 11–25, 1992.

C. C. Kumar, “Signaling by integrin receptors,” *Oncoogene*, vol. 17, no. 11, pp. 1365–1373, 1998.

A. K. Behera, E. Hildebrand, S. Uematsu, S. Akira, J. Coburn, and L. T. Hu, “Identification of a TLR-independent pathway for Borrelia burgdorferi-induced expression of matrix metalloproteinases and inflammatory mediators through binding to integrin\(\alpha3\beta1\),” *The Journal of Immunology*, vol. 177, no. 1, pp. 657–664, 2006.

S. Al-Okla, C. Chatenay-Rivaud, J.-P. Klein, and D. Wachsmann, “Involvement of α5β1 integrins in interleukin 8 production induced by oral viridans streptococcal protein I/II in cultured endothelial cells,” *Cellular Microbiology*, vol. 1, no. 2, pp. 157–168, 1999.

T. E. Secott, T. L. Lin, and C. C. Wu, “Mycobacterium avium subsp. paratuberculosis fibronectin attachment protein facilitates M-cell targeting and invasion through a fibronectin bridge with host integrins,” *Infection and Immunity*, vol. 72, no. 7, pp. 3724–3732, 2004.

T. Vorup-Jensen, C. V. Carman, M. Shimaoka, P. Schuck, J. Svitel, and T. A. Springer, “Exposure of acidic residues as a danger signal for recognition of fibrinogen and other macromolecules by integrin α\(\alpha2\)β\(\beta1\),” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, no. 5, pp. 1614–1619, 2005.

K. Suehiro, J. Mizuguchi, K. Nishiyama, S. Iwanaga, D. H. Farrell, and S. Ohtaki, “Fibrinogen binds to integrin α\(\alpha2\)β\(\beta1\) via the carboxyl-terminal RGD site of the Aα-chain,” *Journal of Biochemistry*, vol. 128, no. 4, pp. 705–710, 2000.

B. B. Gowen, T. K. Borg, A. Ghaffar, and E. P. Mayer, “Selective adhesion of macrophages to denatured forms of type I collagen is mediated by scavenger receptors,” *Matrix Biology*, vol. 19, no. 1, pp. 61–71, 2000.

T. Guo, W. Kang, D. Xiao, R. Duan, W. Zhi, and J. Weng, “Molecular docking characterization of a four-domain segment of human fibronectin encompassing the RGD loop with hydroxyapatite,” *Molecules*, vol. 19, no. 1, pp. 149–158, 2013.

A. Zanetti, G. Conforti, S. Hess et al., “Clustering of vitronectin and RGD peptides on microspheres leads to engagement of integrins on the luminal aspect of endothelial cell membrane,” *Blood*, vol. 84, no. 4, pp. 1116–1123, 1994.

C. A. Hoesli, A. Garnier, P.-M. Janeu, P. Chevallier, C. Duchesne, and G. Laroche, “A fluorophore-tagged RGD peptide to control endothelial cell adhesion to micropatterned surfaces,” *Biomaterials*, vol. 35, no. 3, pp. 879–890, 2014.

L. Tang, “Mechanisms of fibrinogen domains: biomaterial interactions,” *Journal of Biomaterials Science, Polymer Edition*, vol. 9, no. 12, pp. 1257–1266, 1998.

M. Yaseen, X. Zhao, A. Freund, A. M. Seifalian, and J. R. Lu, “Surface structural conformations of fibrinogen polypeptides for improved biocompatibility,” *Biomaterials*, vol. 31, no. 14, pp. 3781–3792, 2010.

F. Barbé, T. Douglas, and M. Saleh, “Advances in Nod-like receptors (NLR) biology,” *Cytokine & Growth Factor Reviews*, vol. 25, no. 6, pp. 681–697, 2014.

S. Akira, “Mammalian Toll-like receptors,” *Current Opinion in Immunology*, vol. 15, no. 1, pp. 5–11, 2003.

M. Oosting, S.-C. Cheng, J. M. Bolscher et al., “Human TLR10 is an anti-inflammatory pattern-recognition receptor,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 111, no. 42, pp. E4478–E4484, 2014.

M. Oldenburg, A. Krüger, R. Ferstl et al., “TLR13 recognizes bacterial 23S rRNA devoid of erythromycin resistance—forming modification,” *Science*, vol. 337, no. 6098, pp. 1111–1115, 2012.

R. Medzhitov, “Toll-like receptors and innate immunity,” *Nature Reviews Immunology*, vol. 1, no. 2, pp. 135–145, 2001.

K. Takeda, T. Kaisho, and S. Akira, “Toll-like receptors,” *Annual Review of Immunology*, vol. 21, pp. 335–376, 2003.
[174] T. Kawai and S. Akira, “The role of pattern-recognition receptors in innate immunity: update on toll-like receptors,” Nature Immunology, vol. 11, no. 5, pp. 573–384, 2010.

[175] R. Maitra, C. C. Clement, B. Scharf et al., “Endosomal damage and TLR2 mediated inflammasome activation by alkane particles in the generation of aseptic osteolysis,” Molecular Immunology, vol. 47, no. 2-3, pp. 175–184, 2009.

[176] T. Lähdeoja, J. Pajarinen, V.-P. Kouri, T. Sillat, J. Salo, and Y. T. Konttinen, “Toll-like receptors and aseptic loosening of hip endoprosthesis—a potential to respond against danger signals?” Journal of Orthopaedic Research, vol. 28, no. 2, pp. 184–190, 2010.

[177] Y. Tamaki, Y. Takakubo, K. Goto et al., “Increased expression of toll-like receptors in aseptic loose periprosthetic tissues and septic synovial membranes around total hip implants,” Journal of Rheumatology, vol. 36, no. 3, pp. 598–606, 2009.

[178] R. D. Valladeres, C. Nich, S. Zwienenberger et al., “Toll-like receptors-2 and 4 are overexpressed in an experimental model of particle-induced osteolysis,” Journal of Biomedical Materials Research, Part A, vol. 102, no. 9, pp. 3004–3011, 2014.

[179] R. Maitra, C. C. Clement, G. M. Crisi, N. Cobelli, and L. Santambrogio, “Immunogenicity of modified alkane polymers is mediated through TLR1/2 activation,” PLoS ONE, vol. 3, no. 6, Article ID e2438, 2008.

[180] B. Shokouhi, C. Coban, V. Hasirci et al., “The role of multiple toll-like receptor signalling cascades on interactions between biomedical polymers and dendritic cells,” Biomaterials, vol. 31, no. 22, pp. 5759–5771, 2010.

[181] T. H. Rogers and J. E. Babensee, “Altered adherent leukocyte profile on biomaterials in Toll-like receptor 4 deficient mice,” Biomaterials, vol. 31, no. 4, pp. 594–601, 2010.

[182] S.-Y. Seong and P. Matzinger, “Hydrophobicity: an ancient immunogenecity of modified alkane polymers,” Biomaterials, vol. 31, no. 4, pp. 594–601, 2010.

[183] A. S. Hoffman, “Principles governing biomolecule interactions at foreign interfaces,” Journal of Biomedical Materials Research, vol. 8, no. 3, pp. 77–83, 1974.

[184] A. M. Piccinni and K. S. Midwood, “DAMPening inflammation by modulating TLR signalling,” Mediators of Inflammation, vol. 2010, Article ID 672395, 21 pages, 2010.

[185] S. T. Smiley, J. A. King, and W. W. Hancock, “Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4,” Journal of Immunology, vol. 167, no. 5, pp. 2887–2894, 2001.

[186] C. P. Hodgkinson, K. Patel, and S. Ye, “Functional Toll-like receptor 4 mutations modulate the response to fibrinogen,” Thrombosis and Haemostasis, vol. 100, no. 2, pp. 301–307, 2008.

[187] Y. Okamura, M. Watari, E. S. Jerud et al., “The extra domain A of fibronectin activates Toll-like receptor 4,” The Journal of Biological Chemistry, vol. 276, no. 13, pp. 10229–10233, 2001.

[188] V. O. Millien, W. Lu, J. Shaw et al., “Cleavage of fibrinogen by proteinases elicits allergic responses through toll-like receptor 4,” Science, vol. 341, no. 6147, pp. 792–796, 2013.

[189] R. M. Kelsh and P. J. McKearn-Longo, “Topographical changes in extracellular matrix: activation of TLR4 signaling and solid tumor progression,” Trends in Cancer Research, vol. 9, pp. 1-13, 2013.

[190] M. M. Khan, C. Gandhi, N. Chauhan et al., “Alternatively-spliced extra domain a of fibronectin promotes acute inflammation and brain injury after cerebral ischemia in mice,” Stroke, vol. 43, no. 5, pp. 1376–1382, 2012.

[191] J. S. Park, D. Svetkauskaite, Q. He et al., “Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein,” The Journal of Biological Chemistry, vol. 279, no. 9, pp. 7370–7377, 2004.

[192] J. S. Park, F. Gamboni-Robertson, Q. He et al., “High mobility group box 1 protein interacts with multiple Toll-like receptors,” The American Journal of Physiology—Cell Physiology, vol. 290, no. 3, pp. C917–C924, 2006.

[193] M. W. Laschke, V. Augustin, S. Kleer, T. Tschernig, and M. D. Menger, “Locally applied macrophage-activating lipopeptide-2 (MALP-2) promotes early vascularization of implanted porous polyethylene (Medpor),” Acta Biomaterialia, vol. 10, no. 11, pp. 4661–4669, 2014.

[194] M. Kulka and D. D. Metcalfe, “TLR3 activation inhibits human mast cell attachment to fibronectin and vitronectin,” Molecular Immunology, vol. 43, no. 10, pp. 1579–1586, 2006.

[195] S. R. Jacobs and B. Danania, “NLRs, inflammasomes, and viral infection,” Journal of Leukocyte Biology, vol. 92, no. 3, pp. 469–477, 2012.

[196] F. Martinon, A. Mayor, and J. Tschopp, “The inflammasomes: guardians of the body,” Annual Review of Immunology, vol. 27, pp. 229–265, 2009.

[197] M. R. de Zoete, N. W. Palm, S. Zhu, and R. A. Flave, “Inflammasomes,” Cold Spring Harbor Perspectives in Biology, vol. 6, no. 12, Article ID a016287, 2014.

[198] F. Martinon, K. Burns, and J. Tschopp, “The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β,” Molecular Cell, vol. 10, pp. 417–426, 2002.

[199] R. L. Brunette, J. M. Young, D. G. Whitley, I. E. Brodsky, H. S. Malik, and D. B. Stetson, “Extensive evolutionary and functional diversity among mammalian AIM2-like receptors,” The Journal of Experimental Medicine, vol. 209, no. 11, pp. 1969–1983, 2012.

[200] V. Hornung, A. Ablasser, M. Charrel-Dennis et al., “AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC,” Nature, vol. 458, no. 7237, pp. 514–518, 2009.

[201] T. Jin, A. Perry, P. Smith, J. Jiang, and T. S. Xiao, “Structure of the absent in melanoma 2 (AIM2) pyrin domain provides insights into the mechanisms of AIM2 autoinhibition and inflammasome assembly,” The Journal of Biological Chemistry, vol. 288, no. 19, pp. 13225–13235, 2013.

[202] T. Fernandes-Alnemri, J.-W. Yu, P. Datta, J. Wu, and E. S. Alnemri, “AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA,” Nature, vol. 458, no. 7237, pp. 509–513, 2009.

[203] L. Franchi, T. Eigenbrod, R. Muñoz-Planillo, and G. Nuñez, “The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis,” Nature Immunology, vol. 10, no. 3, pp. 241–247, 2009.

[204] M. Lamkanfi and V. M. Dixit, “Mechanisms and functions of inflammasomes,” Cell, vol. 157, no. 5, pp. 1013–1022, 2014.

[205] S. J. Riedl and G. S. Salvesen, “The apoptosome: signalling platform of cell death,” Nature Reviews Molecular Cell Biology, vol. 8, no. 5, pp. 405–413, 2007.

[206] A. Lu and H. Wu, “Structural mechanisms of inflammasome assembly,” FEBS Journal, vol. 282, no. 3, pp. 435–444, 2015.

[207] N. Kayagaki, S. Warming, M. Lamkanfi et al., “Non-canonical inflammasome activation targets caspase-11,” Nature, vol. 479, no. 7371, pp. 117–121, 2011.
L. Liu, M. Yang, R. Kang et al., "HMGB1-DNA complex-induced autophagy limits AIM2 inflammasome activation through RAGE," Biochemical and Biophysical Research Communications, vol. 450, no. 1, pp. 851–856, 2014.

M. K. Kukkonen, T. Vehmas, P. Piirilä, and A. Hirvonen, "Genes involved in innate immunity associated with asbestos-related fibrotic changes," Occupational & Environmental Medicine, vol. 71, no. 1, pp. 48–54, 2014.

C. C. Leung, I. T. S. Yu, and W. Chen, "Silicosis," The Lancet, vol. 379, no. 9830, pp. 2008–2018, 2012.

S. L. Cassel, S. C. Eisenbarth, S. S. Iyer et al., "The Nalp3 inflammasome is essential for the development of silicosis," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 26, pp. 9035–9040, 2008.

R. F. Hamilton Jr., S. A. Thakur, and A. Holiian, "Silica binding and toxicity in alveolar macrophages," Free Radical Biology & Medicine, vol. 44, no. 7, pp. 1246–1258, 2008.

P. B. Kopnin, I. V. Kravchenko, V. A. Furalyov, L. N. Pylev, and B. P. Kopnin, "Cell type-specific effects of asbestos on intracellular ROS levels, DNA oxidation and G1 cell cycle checkpoint," Oncogene, vol. 23, no. 54, pp. 8834–8840, 2004.

J. K. Thompson, C. M. Westbom, M. B. MacPherson et al., "Asbestos modulates thioredoxin-thioredoxin interacting protein interaction to regulate inflammasome activation," Particle and Fibre Toxicology, vol. 11, no. 1, article 24, 2014.

A. C. Reisetter, L. V. Stebounova, J. Baltrusaitis et al., "Induction of inflammasome-dependent pyroptosis by carbon black nanoparticles," The Journal of Biological Chemistry, vol. 286, no. 24, pp. 21844–21852, 2011.

O. Lunov, T. Syrovets, C. Loos et al., "Amino-functionalized polystyrene nanoparticles activate the NLRP3 inflammasome in human macrophages," ACS Nano, vol. 5, no. 12, pp. 9648–9657, 2011.

L. Burton, D. Paget, N. B. Binder et al., "Orthopedic wear debris mediated inflammatory osteolysis is mediated in part by NALP3 inflammasome activation," Journal of Orthopaedic Research, vol. 31, no. 1, pp. 73–80, 2013.

M. Winter, H.-D. Beer, V. Hornung, U. Kärmer, R. P. F. Schins, and I. Förster, "Activation of the inflammasome by amorphous silica and TiO2 nanoparticles in murine dendritic cells," Nanotoxicology, vol. 5, no. 3, pp. 326–340, 2011.

M. S. Caicedo, L. Samelko, K. McAllister, J. J. Jacobs, and N. J. Hallah, "Increasing both CoCrMo-alloy particle size and surface irregularity induces increased macrophage inflammasome activation in vitro potentially through lysosomal destabilization mechanisms," Journal of Orthopaedic Research, vol. 31, no. 10, pp. 1633–1642, 2013.

E.-J. Yang, S. Kim, J. S. Kim, and I.-H. Choi, "Inflammasome formation and IL-1β release by human blood monocytes in response to silver nanoparticles," Biomaterials, vol. 33, no. 28, pp. 6858–6867, 2012.

N. Cobelli, B. Scharf, G. M. Crisi, J. Hardin, and L. Santambrogio, "Mediators of the inflammatory response to joint replacement devices," Nature Reviews Rheumatology, vol. 7, no. 10, pp. 600–608, 2011.

A. Rodriguez, H. Meyerson, and J. M. Anderson, "Quantitative in vivo cytokine analysis at synthetic biomaterial implant sites," Journal of Biomedical Materials Research. Part A, vol. 89, no. 1, pp. 152–159, 2009.

A. D. Lynn and S. J. Bryant, "Phenotypic changes in bone marrow-derived murine macrophages cultured on PEG-based hydrogels activated or not by lipopolysaccharide," Acta Biomaterialia, vol. 7, no. 1, pp. 123–132, 2011.
[332] M. J. Dalby, “Topographically induced direct cell mechanotransduction,” Medical Engineering & Physics, vol. 27, no. 9, pp. 730–742, 2005.

[333] M.-H. Kim, Y. Sawada, M. Taya, and M. Kino-o-ka, “Influence of surface topography on the human epithelial cell response to micropatterned substrates with convex and concave architectures,” Journal of Biological Engineering, vol. 8, no. 1, article 13, 2014.

[334] L. E. McNamara, T. Sjöström, K. Seunarine, R. D. Meek, B. Su, and M. J. Dalby, "Investigation of the limits of nanoscale filopodial interactions," Journal of Tissue Engineering, vol. 5, 2014.

[335] M. J. Dalby, M. O. Riehle, D. S. Sutherland, H. Agheli, and A. S. G. Curtis, “Changes in fibroblast morphology in response to nano-columns produced by colloidal lithography," Biomaterials, vol. 25, no. 23, pp. 5415–5422, 2004.

[336] P. K. Mattila and P. Lappalainen, “Filopodia: molecular architecture and cellular functions," Nature Reviews Molecular Cell Biology, vol. 9, no. 6, pp. 446–454, 2008.

[337] B. J. Papenburg, E. D. Rodrigues, M. Wessling, and D. Stamatialis, "Insights into the role of material surface topography and wettability on cell-material interactions," Soft Matter, vol. 6, no. 18, pp. 4377–4388, 2010.

[338] D. W. Baker, X. Liu, H. Weng, C. Luo, and L. Tang, “Fibroblast/fibrocyte: surface interaction dictates tissue reactions to micropillar implants," Biomacromolecules, vol. 12, no. 4, pp. 997–1005, 2011.

[339] Z. Jahed, S. Molladavoodi, B. B. Seo, M. Gorbet, T. Y. Tsui, and M. R. K. Mofrad, “Cell responses to metallic nanostructure arrays with complex geometries," Biomaterials, vol. 35, no. 34, pp. 9363–9371, 2014.

[340] S. Vanni, H. Hirose, H. Barelli, B. Antonny, and R. Gautier, "A sub-nanometre view of how membrane curvature and composition modulate lipid packing and protein recruitment," Nature Communications, vol. 5, article 4916, 2014.

[341] B. Antonny, “Mechanisms of membrane curvature sensing," Annual Review of Biochemistry, vol. 80, pp. 101–123, 2011.

[342] H. T. McMahon and J. L. Gallop, “Membrane curvature and mechanisms of dynamic cell membrane remodelling," Nature, vol. 438, no. 7068, pp. 590–596, 2005.

[343] R. Muñoz-Planillo, P. Kufa, G. Martinez-Colón, B. Smith, T. Rajendiran, and G. Núñez, “K’ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter," Immunity, vol. 38, no. 6, pp. 1142–1153, 2013.

[344] L. Zhang, Z. Cao, T. Bai et al., “Zwitterionic hydrogels implanted in mice resist the foreign-body reaction," Nature Biotechnology, vol. 31, no. 6, pp. 553–556, 2013.

[345] K. S. Jones, “Effects of biomaterial-induced inflammation on fibrosis and rejection," Seminars in Immunology, vol. 20, no. 2, pp. 130–136, 2008.
